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Introduction {#sec1}
============

Clinical presentations of COVID-19 are highly variable, and while the majority of patients experiences mild to moderate symptoms, 10%--20% of patients develop pneumonia and severe disease ([@bib43]; [@bib126]; [@bib134]). Clinical deterioration with respiratory failure and acute respiratory distress syndrome (ARDS) typically develops in the second week of disease. This kinetic may suggest a role for secondary immune responses in the development of severe COVID-19 ([@bib90]). However, the exact mechanisms that govern the pathophysiology of the different disease courses of COVID-19 remain ill-defined.

Single-cell studies of bronchoalveolar lavage samples have suggested a complex dysregulation of the pulmonary immune response in severe COVID-19 ([@bib20]; [@bib63]). Overall, systemic inflammation is linked to an unfavorable clinical course of disease and the development of severe COVID-19 ([@bib33]; [@bib68]; [@bib90]). SARS-CoV-2 infection induces specific T cell and B cell responses, which is reflected by elevation of SARS-CoV-2 peptide-specific T cells ([@bib12]; [@bib34]) and the production of SARS-CoV-2-specific antibodies ([@bib67]; [@bib88]; [@bib103]). Patients with severe COVID-19 have high systemic levels of inflammatory cytokines, particularly interleukin (IL)-6 and IL-1β ([@bib19]; [@bib33]; [@bib68]; [@bib90]), whereas interferon (IFN) responses appear blunted, as shown by whole blood transcriptomics ([@bib36]) and plasma profiling ([@bib120]). A number of studies and regular clinical observations indicate an increase of neutrophils and a decrease of non-classical (CD14^lo^CD16^hi^) monocytes in severe COVID-19 ([@bib36]; [@bib80]; [@bib104]). Profound immune dysregulation is commonly observed in severe infections and sepsis, characterized by a progression from hyperinflammatory states to immunosuppression ([@bib98]; [@bib102]), and similar mechanisms have been proposed for severe COVID-19 ([@bib33]). Yet, comprehensive insights into the immunopathology of severe COVID-19 are still missing. Exacerbated immune responses played a major role in the pathophysiology of SARS, leading to severe lung injury and respiratory failure ([@bib92]). Mitigation of immunodysregulation is therefore viewed as a major therapeutic avenue for the treatment and prevention of severe COVID-19 ([@bib29]; [@bib45]). In support of this view, a recent multicenter study reported that dexamethasone treatment significantly reduced mortality in hospitalized patients with COVID-19, particularly in patients on mechanical ventilation ([@bib41]). Previous studies of peripheral blood mononuclear cell (PBMC) transcriptomes in a small number of patients with COVID-19 revealed changes in several cellular compartments, including monocytes, natural killer (NK) cells, dendritic cells (DCs), and T cells ([@bib59]; [@bib128]).

The heterogeneity of clinical manifestations and the complexity of immune responses to COVID-19 highlight the need for detailed analyses using high-resolution techniques and well-characterized clinical cohorts. We hypothesized that distinct responses, particularly within the innate immune system, underlie the different clinical trajectories of COVID-19 patients ([@bib20]; [@bib54]; [@bib74]; [@bib75]). Here, we used single-cell transcriptomics and single-cell proteomics to analyze immune responses in blood samples in two independent cohorts of COVID-19 patients.

Activated HLA-DR^hi^CD11c^hi^CD14^+^ monocytes were increased in patients with mild COVID-19, similar to patients with SARS-CoV-2 negative flu-like illness ("FLI"). In contrast, monocytes characterized by low expression of *HLA-DR*, and marker genes indicative of anti-inflammatory functions (e.g., *CD163* and *PLAC8*) appeared in patients with severe COVID-19. The granulocyte compartment was profoundly altered in severe COVID-19, marked by the appearance of neutrophil precursors due to emergency myelopoiesis, dysfunctional neutrophils expressing PD-L1, and exhibiting an impaired oxidative burst response. Collectively, our study links highly dysregulated myeloid cell responses to severe COVID-19.

Results {#sec2}
=======

Dual Center Cohort Study to Assess Immunological Alterations in COVID-19 Patients {#sec2.1}
---------------------------------------------------------------------------------

In order to probe the divergent immune responses in mild versus severe COVID-19, we analyzed blood samples collected from independent patient cohorts at two university medical centers in Germany. Samples from the Berlin cohort (cohort 1) ([@bib55]), were analyzed by mass cytometry (CyTOF) and single-cell RNA-sequencing (scRNA-seq) using a droplet-based single-cell platform (10x Chromium), while samples from the Bonn cohort (cohort 2) were analyzed by multi-color flow cytometry (MCFC) and on a microwell-based scRNA-seq system (BD Rhapsody). We analyzed a total of 24 million cells by their protein markers and \>328,000 cells by scRNA-seq in 242 samples from 53 COVID-19 patients and 56 controls, including 8 patients with FLI ([Figures 1](#fig1){ref-type="fig"} A, 1B, and [S1](#figs1){ref-type="fig"} A; [Table S1](#mmc1){ref-type="supplementary-material"}).Figure 1Cohort Definition and Single-Cell Multi-omics Analysis Strategy(A) Pipeline for control and COVID-19 blood samples of the two cohorts (see also [Table S1](#mmc1){ref-type="supplementary-material"}). Whole blood samples were subjected to red blood cell (RBC) lysis and processed for CyTOF mass cytometry (two antibody panels), multi-color flow cytometry (MCFC), or scRNA-seq (BD Rhapsody). PBMCs were isolated by density centrifugation and processed directly or after frozen storage, labeled with cell hashing antibodies and loaded on droplet-based (10x) or microwell-based (BD Rhapsody) scRNA-seq platforms. Box (bottom left): number of subjects in each cohort. Boxes (on the right): number of samples analyzed with each technique.(B) Number of samples per technique summarized across cohorts, divided by disease severity according to WHO ordinal scale and by the time after onset of first symptoms (early: days 0--10, late: \>day 11).(C) UMAP of CD45^+^ leukocytes, down-sampled to 70,000 cells, from mass cytometry using antibody panel 2 (30 markers, [Table S2](#mmc2){ref-type="supplementary-material"}). Cells are colored according to donor origin (blue, age-matched controls; gray, FLI; yellow, mild COVID-19; red, severe COVID-19) and major lineage subtypes.(D) Box and whisker (10--90 percentile) plots of major cell lineage composition in whole blood from FLI (n = 8), COVID-19 patients with mild (n = 8) or severe disease (n = 9), age-matched controls measured by mass cytometry (ctrl CyTOF, n = 9) or by flow cytometry (ctrl flow, n = 19) ([@bib56]). Kruskal-Wallis and Dunn's multiple comparison test ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. n.a., not available.See also [Figure S1](#figs1){ref-type="fig"} and [Table S3](#mmc3){ref-type="supplementary-material"}.Figure S1Overview of Sample Analysis Pipeline, Major Leukocyte Lineages Definition, and Quantification by CyTOF and MCFC, Related to [Figure 1](#fig1){ref-type="fig"}A, Overview of the analysis pipeline for scRNA-seq and proteomics of COVID-19 samples.B, High resolution SPADE analysis with 400 target nodes and individual nodes aggregated to the indicated major immune cell lineages according to the expression of lineage specific cell marker such as CD14 for monocytes and CD15 for neutrophils of whole blood samples collected from FLI patients, COVID-19 patients and controls and stained with CyTOF panel 1 and 2, respectively.C, Boxplots of the composition of total granulocytes and non-classical monocytes within whole blood samples from the second cohort of COVID-19 patients showing either mild (n = 3) or severe disease (n = 7) as well as controls (n = 11) measured by flow cytometry. Statistical analysis was performed using unpaired t test. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

We first characterized alterations of the major leukocyte lineages by mass cytometry on whole blood samples from 20 COVID-19 patients collected between day 4 and day 29 after symptom onset and compared them to 10 age- and gender-matched controls and 8 FLI patients. We designed two antibody panels to specifically capture alterations in mononuclear leukocytes (lymphocytes, monocytes, and DCs, panel 1), and in granulocytes ([Table S2](#mmc2){ref-type="supplementary-material"}, panel 2). High-resolution SPADE analysis was performed with 400 target nodes and individual nodes were aggregated into cell subsets based on lineage-specific markers, such as CD14 for monocytes and CD15 for neutrophils ([Figure S1](#figs1){ref-type="fig"}B). Uniform manifold approximation and projection (UMAP) analysis revealed distinct clustering of samples from COVID-19 patients, FLI, and healthy controls, with marked changes of the monocyte and granulocyte compartment ([Figure 1](#fig1){ref-type="fig"}C). Leukocyte lineages were compared in the earliest available samples in COVID-19 patients (days 4--13), FLI, and controls ([Figure 1](#fig1){ref-type="fig"}D; [Table S1](#mmc1){ref-type="supplementary-material"}). Because leukocyte counts were not available for all control samples, we compared the control samples for CyTOF ("ctrl CyTOF") to data from our recently published healthy control cohorts ("ctrl flow") ([@bib56]; [@bib106]). The proportions of all major lineages were highly similar, irrespective of the methodology ([Figure 1](#fig1){ref-type="fig"}D). Cell counts of the published cohort could therefore be used as a reference to report absolute cell counts for leukocyte lineages in COVID-19 samples. In line with recent reports ([@bib8]; [@bib129]), we observed elevated leukocytes and increased proportions of neutrophils in patients with severe COVID-19 ([Figure 1](#fig1){ref-type="fig"}D), whereas only proportional increases in neutrophils were evident in FLI and mild COVID-19 patients ([Figure 1](#fig1){ref-type="fig"}D). Total lymphocytes and T cells were strongly reduced in all COVID-19 and FLI patients, whereas non-classical monocytes were specifically depleted in COVID-19 ([Figure 1](#fig1){ref-type="fig"}D). Increased neutrophils in severe COVID-19 and loss of non-classical monocytes in both mild and severe disease were validated in cohort 2 by MCFC ([Figure S1](#figs1){ref-type="fig"}C; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}).

Thus, SARS-CoV-2 infection is associated with lymphopenia and profound alterations of the myeloid compartment.

Severity-Dependent Alterations of the Myeloid Cell Compartment in COVID-19 {#sec2.2}
--------------------------------------------------------------------------

Given the dramatic changes in various immune cell populations ([Figures 1](#fig1){ref-type="fig"}C and 1D), we next assessed their composition and activation state by droplet-based scRNA-seq in 27 samples from 18 COVID-19 patients (8 mild and 10 severe, cohort 1, [Table S1](#mmc1){ref-type="supplementary-material"}) collected between day 3 and day 20 after symptom onset. A total of 48,266 single-cell transcriptomes of PBMCs were analyzed together with 50,783 PBMCs from publicly available control datasets (21 control donors, [Table S1](#mmc1){ref-type="supplementary-material"}). UMAP and high-resolution cell type classification identified all cell types expected in the mononuclear compartment of blood with a high granularity in the monocytes, identifying five distinct clusters (clusters 0--4) ([Figures 2](#fig2){ref-type="fig"} A and [S2](#figs2){ref-type="fig"} A; [Table S4](#mmc4){ref-type="supplementary-material"}). Monocytes in clusters 0--3 expressed *CD14*, and cluster 4 comprised the non-classical monocytes marked by *FCGR3A* (encoding CD16a) and low expression of *CD14*. Separate visualization of cells in mild and severe cases revealed highly disease severity-specific clusters ([Figure 2](#fig2){ref-type="fig"}B). A distinct subset of *CD14* ^*+*^ monocytes (cluster 1) ([Figure 2](#fig2){ref-type="fig"}A) marked by high expression of *HLA-DRA*, *HLA-DRB1*, and co-stimulatory molecule *CD83* ([Figure S2](#figs2){ref-type="fig"}D), the engagement of which has been linked to prolonged expansion of antigen-specific T cells ([@bib39]), was selectively detected in mild COVID-19 ([Figure 2](#fig2){ref-type="fig"}C). In addition, we identified another closely related *CD14* ^*+*^ *HLA-DR* ^*hi*^ monocyte population (cluster 2), which was characterized by high expression of IFN-stimulated genes (ISGs). However, upon closer analysis, this cluster was found to originate from a single donor with mild COVID-19 ([Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#figs2){ref-type="fig"}D). Both cluster 1 and cluster 2 expressed high levels of ISGs *IFI6* and *ISG15* ([Figure S2](#figs2){ref-type="fig"}D). In patients with severe COVID-19, monocytes showed low expression of *HLA-DR* and high expression of alarmins *S100A8/9/12* (cluster 3, [Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#figs2){ref-type="fig"}D). The most prominent change in severe COVID-19 was the appearance of two distinct cell populations (cluster 5+6), absent in PBMCs of patients with mild COVID-19 and control donors ([Figure 2](#fig2){ref-type="fig"}A). Published markers ([@bib57]; [@bib87]) identified clusters 5 and 6 as neutrophils and immature neutrophils, respectively ([Figures 2](#fig2){ref-type="fig"}A and 2B). Immature neutrophils (cluster 6) expressed *CD24*, *PGLYRP1*, *DEFA3*, and *DEFA4*, whereas neutrophil cluster 5 expressed *FCGR3B* (CD16b), *CXCL8*, and *LCN2* (lipocalin 2) ([Figures 2](#fig2){ref-type="fig"}C and [S2](#figs2){ref-type="fig"}A). Their migration within the PBMC fraction on a density gradient marked these cells as low-density neutrophils (LDNs).Figure 2scRNA-Seq of PBMC from Patients of the Two Independent Cohorts(A) UMAP visualization of scRNA-seq profiles (10x, cohort 1) of 99,049 PBMC from 49 samples (8 mild, 10 severe patients, different time points) and 22 control samples colored according to cell type classification (Louvain clustering), reference-based cell-type annotation, and marker gene expression ([Table S4](#mmc4){ref-type="supplementary-material"}).(B) UMAP shown in (A) colored according to disease severity (yellow, mild COVID-19; red, severe COVID-19).(C) Dot plots of the intersection of the top 20 marker genes sorted by average log fold change determined for the indicated myeloid cell subsets in the PBMC datasets of both cohorts.(D) UMAP visualization of scRNA-seq profiles (BD Rhapsody, cohort 2) of 139,848 PBMCs (50 samples of 8 mild, 9 severe COVID-19; 14 samples of 13 controls; different time points), coloring as in (A) (see also [Figure S2](#figs2){ref-type="fig"}A and [Table S4](#mmc4){ref-type="supplementary-material"}).(E) Box and whisker plots (25--75 percentile) of percentages of cell subsets of total PBMC (per patient). Boxes are colored according to disease group and dots according to the respective cohort of the sample. Dirichlet-multinomial regression adjusted with the Benjamini-Hochberg method, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.See also [Table S1](#mmc1){ref-type="supplementary-material"}.Figure S2Cluster-Specific Marker Gene Expression Shows Inflammatory Activation Signatures of Monocyte Subsets and the Appearance of Neutrophil Subsets in the PBMC Fraction, Related to [Figure 2](#fig2){ref-type="fig"}(A), Dot plots of the top 5 marker genes sorted by average log fold change determined for the clusters depicted in [Figure 2](#fig2){ref-type="fig"}A.(B), Dot plot representation of the top 5 marker genes sorted by average log fold change determined for the clusters depicted in [Figure 2](#fig2){ref-type="fig"}D.C: Heatmap of the Spearman correlation coefficients between myeloid cell subsets in two cohorts, based on the union of top 50 marker genes per cluster.

In the second cohort, PBMCs from 17 COVID-19 patients (8 mild, 9 severe, [Table S1](#mmc1){ref-type="supplementary-material"}), sampled between 2 and 25 days after symptom onset, and 13 controls, were collected for scRNA-seq on a microwell-based platform (BD Rhapsody). High-quality single-cell transcriptomes for 139,848 PBMCs were assessed and their population structure was visualized using UMAP ([Figure 2](#fig2){ref-type="fig"}D; [Table S4](#mmc4){ref-type="supplementary-material"}). Data-driven cell-type classification ([@bib5]) and cluster-specific marker gene expression identified all cell types expected in the PBMC compartment and revealed additional clusters and substructures ([Figures 2](#fig2){ref-type="fig"}D and [S2](#figs2){ref-type="fig"}B). Similar to cohort 1, monocytes exhibited significant plasticity and were subclassified into 5 clusters ([Figure 2](#fig2){ref-type="fig"}D, clusters 0--4). Disease-severity-associated changes seen in cohort 1 were validated in cohort 2 ([Figure 2](#fig2){ref-type="fig"}E). Immature and mature neutrophil clusters were detected in both cohorts (clusters 5--6) and showed near identical marker gene expression ([Figure 2](#fig2){ref-type="fig"}C). Similar to cohort 1, a prominent shift in subpopulation occupancy was observed in the monocyte clusters ([Figures 2](#fig2){ref-type="fig"}D and 2E).

Based on the union of the top 50 genes for monocyte and neutrophil clusters, we found a high correlation between the independently defined functional states within the monocyte compartment, and mature and immature neutrophils in cohort 1 and cohort 2 ([Figure S2](#figs2){ref-type="fig"}C). Violin plot representation of important marker genes illustrated distinct phenotypic states and underscored the high similarity of the two cohorts ([Figure S2](#figs2){ref-type="fig"}D).

Disease-severity-dependent alterations of the monocyte compartment and the appearance of two LDN populations were detected in two cohorts of COVID-19 patients.

Predominance of HLA-DR^hi^CD11c^hi^ Inflammatory Monocytes in Mild and HLA-DR^lo^CD11c^lo^CD226^+^CD69^+^ Monocytes in Severe COVID-19 {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------------

The monocyte compartment is particularly affected by COVID-19, indicated by a loss of CD14^lo^CD16^hi^ non-classical monocytes ([Figures 1](#fig1){ref-type="fig"}C and 1D). Disease-severity-dependent shifts in monocyte activation were identified by scRNA-seq ([Figure 2](#fig2){ref-type="fig"}). We further explored the phenotypic alterations of the monocyte compartment using mass cytometry ([Table S2](#mmc2){ref-type="supplementary-material"}, panel 1) on whole blood samples from COVID-19 patients with a mild or severe disease (n = 8+9), patients with FLI (n = 8), and age- and gender-matched controls (n = 9, all collected within cohort 1, [Table S1](#mmc1){ref-type="supplementary-material"}). Unsupervised cluster analysis using 15 surface antigens and the proliferation marker Ki67 separated the monocyte and DC compartment into 12 main cell clusters ([Figures 3](#fig3){ref-type="fig"}A and 3B). Classical CD14^hi^CD16^−^ monocytes displayed high heterogeneity and separated into seven main subclusters. Most classical monocytes showed high expression of activation markers CD38, CD95, and CXCR3. The four most prevalent clusters (1, 2, 5, and 6) varied according to CD62L, HLA-DR, CD11c, and Ki67 expression, with CD62L and HLA-DR showing a reverse expression pattern ([Figure 3](#fig3){ref-type="fig"}A). Cluster 1 displayed an activated inflammatory phenotype with high co-expression of CD11c and HLA-DR ([@bib10]; [@bib47]). In addition, we observed classical monocyte cell clusters (7, 9, and 10) with high CD226 and CD69 but low HLA-DR expression and thus signs of altered or alternative activation ([@bib26]; [@bib100]; [@bib124]). Among the HLA-DR^lo^ clusters, particularly cluster 7 showed high expression of CD34 indicative of a more immature phenotype. In contrast, the majority of CD14^hi^CD16^+^ intermediate monocyte cell clusters showed high CD11c and HLA-DR expression.Figure 3CD11c^lo^ and HLA-DR^lo^ but CD226^+^CD69^+^ Monocytes in Severe COVID-19(A) Heatmap of CyTOF data (antibody panel 1, cohort 1) covering monocytes and DCs. Main cell, as defined by the numbers 1 to 12, and individual cell clusters are displayed in columns and marker identity is indicated in rows. MSI, marker staining intensity respective expression level, significance level for the following comparisons: (1) controls (ctrl, n = 9) versus COVID-19 (mild and severe, n = 17, first row), (2) mild (n = 8) versus severe (n = 9, second row), (3) FLI (n = 8) versus mild COVID-19 (n = 8, third row), as well as (4) controls (ctrl, n = 9) versus FLI (n = 8) are indicated using a gray scale on top of the heatmap (p value scale next to heatmap). COVID-19 samples collected between days 4 and 13 post-symptom onset ( = first day of sample collection per patient). Abundance testing via generalized mixed effects models and multiple comparison adjustment using the Benjamini-Hochberg procedure and a false discovery rate (FDR) cutoff of 5% across all clusters/subsets and between-group comparisons.(B) UMAP of monocytes and DCs, down-sampled to 70,000 cells, (39 markers, [Table S2](#mmc2){ref-type="supplementary-material"}). Cells are colored according to main cell clusters (1 to 12, colors as in A) as defined in the table, donor origin (blue, controls; gray, FLI; yellow, mild COVID-19; red, severe COVID-19) and expression intensity of HLA-DR, CD11c, CD226, and CD69.(C) Box and whisker (10--90 percentile) plots of main monocyte clusters 1, 10 (CD14^hi^CD16^−^ classical monocytes), 11, and 3 (CD14^hi^CD16^+^ intermediate monocytes) determined by mass cytometry (whole blood, cohort 1): controls (n = 9), FLI patients (n = 8), COVID-19 patients (mild, n = 8; severe, n = 9). Abundance testing via R multcomp and lsmeans packages adjusted using the Benjamini-Hochberg procedure and an FDR-cutoff of 5% across all clusters/subsets and between-group comparisons.(D) Box and whisker (10--90 percentile) plots of CXCR3^+^, HLA-DR^hi^CD11c^hi^, and CD226^+^CD69^+^ monocytes measured by mass cytometry (whole blood, cohort 1): controls (n = 9), FLI patients (n = 8), and COVID-19 patients (mild, n = 8; severe, n = 9). Kruskal-Wallis and Dunn's multiple comparison tests.(E) Boxplot of HLA-DR^hi^CD11c^hi^ monocytes (cohort 2) measured by flow cytometry: COVID-19 (mild, n = 3; severe, n = 7) and age-matched controls (n = 11). Unpaired t test.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}.

Monocytes from COVID-19 patients separated from those of FLI patients and controls ([Figure 3](#fig3){ref-type="fig"}B), mainly based on elevated CD226 and CD69 expression in COVID-19. Monocytes in mild and severe COVID-19 clustered separately, and monocytes from mild COVID-19 clustered closer to monocytes in FLI. FLI patients and mild COVID-19 contained higher proportions of HLA-DR^hi^CD11c^hi^ cells (clusters 3 and 11), and total HLA-DR^hi^CD11c^hi^ monocytes were higher compared to controls and severe COVID-19, reflecting blunted monocyte activation in severe COVID-19, reminiscent of observations in sepsis ([@bib47]) ([Figures 3](#fig3){ref-type="fig"}A, 3C, and 3D). Increased levels of activated HLA-DR^hi^CD11c^hi^ monocytes in mild COVID-19 patients were confirmed by MCFC in cohort 2 ([Figure 3](#fig3){ref-type="fig"}E). In severe COVID-19, we detected increased expression of CD226 and CD69 (cluster 10) and/or decreased expression of HLA-DR, and total CD226^+^CD69^+^ monocytes were elevated compared to controls. Cluster 10 expressed high levels of CD10, which is induced during macrophage differentiation ([@bib44]). Thus, an alternative activation pattern of classical monocytes appeared to be COVID-19-specific and was associated with severe disease. Besides activated lymphocytes, monocytes also upregulate CD69 expression ([@bib26]), which promotes tissue infiltration and retention ([@bib22]). Similarly, CD226 expression on alternatively activated monocytes might also promote diapedesis and tissue infiltration ([@bib100]). Together, this activation pattern may contribute to the reduction of circulating monocytes in COVID-19.

*HLA-DR*^*lo*^ Monocytes Persist in Severe COVID-19 {#sec2.4}
---------------------------------------------------

Next, we dissected COVID-19-associated phenotypic alterations of monocytes by scRNA-seq. Marker genes of the monocyte clusters derived from [Figure 2](#fig2){ref-type="fig"}A showed that mild COVID-19 associated clusters 1 and 2 were characterized by an ISG-driven transcriptional program ([Figure S3](#figs3){ref-type="fig"} A), and gene ontology enrichment analysis (GOEA) assigned these clusters to "type I interferon signaling pathway" ([Figure S3](#figs3){ref-type="fig"}B). A monocyte cluster marked by low expression of *HLA-DR* and high expression of *S100A12* and *CXCL8* (cluster 3, *HLA-DR* ^*lo*^ *S100A* ^*hi*^) was strongly associated with severe COVID-19 ([Figures 2](#fig2){ref-type="fig"}B, [S2](#figs2){ref-type="fig"}D, and [S3](#figs3){ref-type="fig"}A). For further in-depth analysis, we subclustered the monocyte compartment of the PBMC dataset of cohort 2 ([Figures 2](#fig2){ref-type="fig"}D and [S3](#figs3){ref-type="fig"}C; [Table S1](#mmc1){ref-type="supplementary-material"}) resulting in 7 subclusters ([Figure 4](#fig4){ref-type="fig"} A). Cluster 1 was marked by high expression of *HLA-DRA* and *HLA-DRB1* and co-stimulatory molecule *CD83* and was therefore designated *HLA-DR* ^*hi*^ *CD83* ^*hi*^-activated inflammatory monocytes ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S3](#figs3){ref-type="fig"}D, and S3E). We identified two major clusters (0 and 2) and a smaller cluster (6) with low *HLA-DR* expression, which were associated with severe COVID-19 ([Figures 4](#fig4){ref-type="fig"}B, [S3](#figs3){ref-type="fig"}D, and S3E). Low HLA-DR expression is an established surrogate marker of monocyte dysfunction ([@bib123]) which results in reduced responsiveness to microbial stimuli ([@bib122]), suggesting that clusters 0 and 6 are composed of dysfunctional monocytes. Genes of the *S100A* family were expressed in both *HLA-DR* ^*lo*^ clusters ([Figure 4](#fig4){ref-type="fig"}B), albeit to a higher degree in cluster 0 (*HLA-DR* ^*lo*^ *S100A* ^*hi*^, e.g., *S100A12*) (Figures [Figure S2](#figs2){ref-type="fig"}, [Figure S3](#figs3){ref-type="fig"}D and [S3](#figs3){ref-type="fig"}E; [Table S4](#mmc4){ref-type="supplementary-material"}). Cluster 2 monocytes expressed high levels of *SELL* (CD62L) and *CD163* (*HLA-DR* ^*lo*^ *CD163* ^*hi*^) ([Figure 4](#fig4){ref-type="fig"}B), associated with anti-inflammatory macrophage functions ([@bib32]; [@bib70]), as well as pre-maturation markers like *MPO* and *PLAC8* ([Figure 4](#fig4){ref-type="fig"}B), recently linked to immature monocyte states in sepsis patients ([@bib99]). In line with these findings, clusters 0, 2, and 6 were significantly enriched in a gene signature derived from sepsis-associated monocytes ([Figure 4](#fig4){ref-type="fig"}C) ([@bib99]). Moreover, blood monocytes isolated from COVID-19 patients showed a blunted cytokine response to LPS stimulation, particularly monocytes from patients with severe COVID-19 ([Figure 4](#fig4){ref-type="fig"}D). Accordingly, *HLA-DR* ^*lo*^ monocyte clusters (0, 2, and 6) were detected almost exclusively in severe COVID-19 ([Figure 4](#fig4){ref-type="fig"}E). We next analyzed time-dependent cluster occupancies per patient in cohort 2 ([Figures 4](#fig4){ref-type="fig"}E and 4F). Activated *HLA-DR* ^*hi*^ *CD83* ^*hi*^ monocytes (cluster 1) were found in all cases of mild COVID-19, even at late time points ([Figures 4](#fig4){ref-type="fig"}E and 4F). In contrast, *HLA-DR* ^lo^ *CD163* ^*hi*^ monocytes (cluster 2) were present mainly early in severe disease, while *HLA-DR* ^lo^ *S100A* ^*hi*^ monocytes (cluster 0) dominated the late phase of disease ([Figures 4](#fig4){ref-type="fig"}E and 4F). Violin plots of *ISG* ([Figure S3](#figs3){ref-type="fig"}D) and visualization of marker genes ([Figure S3](#figs3){ref-type="fig"}E) indicated differential expression patterns of IFN signature genes in individual monocyte clusters. To reveal the kinetics of ISG expression, we plotted the expression of *ISG15* and *IFI6* in the complete monocyte population for all patients that had been sampled at least twice ([Figure 4](#fig4){ref-type="fig"}G). Expression levels were highest at early time points and consistently decreased over time, clearly indicating that the IFN response in COVID-19 is inversely linked to disease severity and time ([Figures S3](#figs3){ref-type="fig"}F and S3G). In contrast, decreased expression of *HLA-DRA* and *HLA-DRB1* in severe COVID-19 is evident early on and sustained over time.Figure S3Transcriptional Differences of Monocytes from Mild and Severe COVID-19, Related to [Figure 4](#fig4){ref-type="fig"}A, Dot plot of the top 10 marker genes sorted by average log fold change of the clusters within the monocyte space of cohort 1 (related to [Figure 2](#fig2){ref-type="fig"}, [Table S4](#mmc4){ref-type="supplementary-material"}).B, Gene ontology enrichment analysis based on the complete marker genes obtained for each monocyte cluster of cohort 1, showing the top 10 significant terms enriched in each cluster ranked by adjusted p values.C, Back-mapping of monocyte clusters of cohort 2 ([Figure 4](#fig4){ref-type="fig"}C) onto the PBMC UMAP of cohort 2 ([Figure 2](#fig2){ref-type="fig"}D). The legend shows the association of the colors to the clusters together with the labeling of the clusters based on expressed marker genes (according to [Figures 2](#fig2){ref-type="fig"} and [S3](#figs3){ref-type="fig"}D--S3F).D, Violin plots of marker gene expression in the monocyte clusters identified in the complete PBMC space of cohort 2 ([Figures 2](#fig2){ref-type="fig"}C and 2D)E, Dot plot of the top 10 marker genes sorted by average log fold change calculated for the monocyte clusters ([Figure 4](#fig4){ref-type="fig"}C).F, Violin plots of the *IFI6* and *ISG15* expression in cells of mild and severe patients, additionally divided into early (1-10 days after disease onset) and late (\> 10 days after disease onset). Statistical analysis was performed using Wilcoxon Rank Sum test adjusted with the Bonferroni method, ^∗∗∗∗^p \< 0.0001.G, Violin plots showing the time-dependent change of *HLA-DRA* and *HLA-DRB1* expression in the monocyte population of cohort 1 (mild: n = 4; severe: n = 4) and cohort 2 (mild: n = 5; severe: n = 7). Mild samples are colored in yellow, severe samples in red and controls in blue, with the latter shown as reference violin plots representing the expression of all control monocytes in the respective cohort (cohort 1: n = 22, cohort 2: n = 6).Figure 4Disease-Related Longitudinal Changes in Monocyte Transcriptomes(A) UMAP visualization of monocytes (43,772 cells; from [Figure 2](#fig2){ref-type="fig"}C, cohort 2); 46 samples from controls (n = 6) and COVID-19 (mild, n = 7; severe, n = 8). Cells are colored according to the identified monocyte clusters (Louvain clustering, [Table S4](#mmc4){ref-type="supplementary-material"}).(B) Visualization of scaled expression of selected genes (monocyte markers, [Figures 2](#fig2){ref-type="fig"} and [S3](#figs3){ref-type="fig"}E) using the UMAP defined in (A). Three main clusters defining monocytes in COVID-19 (*HLA-DR*^*lo*^*CD163*^*hi*^, *HLA-DR*^*lo*^*S100A*^*hi*^, and *HLA-DR*^*hi*^*CD83*^*hi*^ monocytes) indicated by dashed areas.(C) AUCell-based enrichment of a gene signature from sepsis-associated monocytes (MS1 cells) ([@bib99]), violin plots of the area under the curve (AUC) scores. Horizontal lines: median of the respective AUC scores per cluster.(D) Cytokine detection of IL-1β, tumor necrosis factor alpha (TNF)-α, and IL-12 in supernatants of purified monocytes (controls, ctrl, n = 3; COVID-19, mild, n = 3, and severe, n = 3) after 8 h *in vitro* incubation with or without 1 ng/mL LPS. Mean ± standard deviation. Kruskal-Wallis test adjusted with Benjamini-Hochberg method, ^∗^p \< 0.05.(E) Mapping of monocytes derived from COVID-19 patients (mild early, mild late, severe early, and severe late) onto UMAP from (A), coloring according to monocyte cluster identity.(F) Cluster occupancy over time for patients with longitudinal scRNA-seq data (mild, n = 5; severe, n = 7), coloring according to (A). Vertical dashed lines: time points of sampling. Red bar, WHO ordinal scale; *X*, patient deceased. Patient IDs on the right side, grouping according to disease severity. Bold dotted line (right): patients classified as mild at initial sampling developing severe disease over time.(G) Time-dependent change of *IFI6* and *ISG15* expression (violin-plots) in monocytes of cohort 1 (mild \[yellow\], n = 4; severe \[red\], n = 4), cohort 2 (mild \[yellow\], n = 5; severe \[red\], n = 7), and controls (cohort 1, n = 22, cohort 2, n = 6).(H) Network representation of marker genes and their predicted upstream transcriptional regulators for monocyte clusters 0, 1, 2, and 3. Edges: predicted transcriptional regulation. Transcription factors (TFs, inner circle) and predicted target genes (outer circle) represented as nodes sized and colored according to the scaled expression level across all clusters. Selected TFs and genes labeled based on connectivity and literature mining. Numbers in the center refer to clusters defined in (A).See also [Figure S1](#figs1){ref-type="fig"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc4){ref-type="supplementary-material"}.

Transcription factor prediction indicated a STAT signaling-driven gene expression program in monocytes in COVID-19 ([Figure 4](#fig4){ref-type="fig"}H), with additional regulation by CEBPD and CEBPE, which have been implicated in gene expression programs of sepsis-associated monocytes ([@bib99]). STAT3 was predicted as a specific regulator of genes enriched in *HLA-DR* ^*lo*^ *CD163* ^*hi*^ and *HLA-DR* ^*lo*^ *S100A* ^*hi*^ monocytes (clusters 2 and 0), in line with their immunosuppressive phenotype.

Taken together, dynamic changes of monocyte phenotypes were associated with COVID-19 disease severity and time after onset of disease.

Low-Density Neutrophils Emerge in Severe COVID-19 Patients Indicative of Emergency Myelopoiesis {#sec2.5}
-----------------------------------------------------------------------------------------------

PBMCs derived from blood samples of patients with severe COVID-19 contained two distinct clusters of LDNs ([Figures 2](#fig2){ref-type="fig"}A, clusters 5 and 6, and [2](#fig2){ref-type="fig"}D, clusters 5 and 6). LDNs were slightly more frequent in cohort 1, and we analyzed these cells in more detail. Subsampling of all LDNs ([Figure 5](#fig5){ref-type="fig"} A; [Table S1](#mmc1){ref-type="supplementary-material"}) and re-clustering the cells revealed 8 transcriptionally distinct cell clusters ([Figures 5](#fig5){ref-type="fig"}A and 5B; [Table S4](#mmc4){ref-type="supplementary-material"}). Based on published markers for pro- and pre-neutrophils, and mature neutrophils ([@bib57]; [@bib87]; [@bib107]) we identified clusters 4 and 6 as *CD81* ^*+*^ *SPN*(CD43)^*+*^ *FUT4*(CD15)^*+*^ *CD63* ^*+*^ *CEACAM8*(CD66b)^*+*^ pro-neutrophils, clusters 3 and 5 as *ITGAM*(CD11b)^*+*^ *CEACAM8*(CD66b)^*+*^ *CD101* ^*+/−*^ pre-neutrophils, and the remaining clusters as mature neutrophils ([Figure S4](#figs4){ref-type="fig"} A). Accordingly, pro- and pre-neutrophils were enriched for transcriptional signatures of neutrophil progenitors derived from published single-cell data ([Figure 4](#fig4){ref-type="fig"}C) ([@bib91]; [@bib95]), and pro-neutrophils in clusters 4 and 6 showed the highest proportion of cells with a proliferative signature ([Figure S4](#figs4){ref-type="fig"}B). Clusters 0, 1, and 2 (originally in cluster 4 in [Figure 2](#fig2){ref-type="fig"}A) expressed mature neutrophil markers *FCGR3B* (CD16) and *MME* (CD10) ([Figure S4](#figs4){ref-type="fig"}A).Figure 5Immature and Dysfunctional Low-Density Neutrophils Emerge in PBMC(A) UMAP representation and clustering of low-density neutrophils (LDNs, 3,154 cells) in PBMCs (cohort 1, clusters 5/6, [Figure 2](#fig2){ref-type="fig"}A) from 21 samples (6 mild, 10 severe COVID-19). Left panel: cluster affiliation in [Figure 2](#fig2){ref-type="fig"}A. Right panel: data-driven clustering and cell type nomenclature based on marker genes ([Table S4](#mmc4){ref-type="supplementary-material"}).(B) Dot plot of the top 10 marker genes sorted by average log fold change associated with the neutrophil clusters identified in (A).(C) Signature enrichment scores of single-cell data from neutrophil progenitors ([@bib91]; [@bib95]) in LDN clusters, plotted as violin plots. The lines in the violin plots represent the median of the respective AUC scores per cluster and the 0.25 and 0.75 quantiles. The ribosomal^hi^-specific cluster 7 was excluded from this analysis.(D) Violin plots of expression of selected activation genes across the neutrophil clusters identified in (A). The panel of genes was chosen based on their described role in neutrophil extracellular trap formation (*PRTN3*, *ELANE*, *MPO*, and *PADI4*) and neutrophil activation and dysregulation (*CD24*, *OLFM4*, *LCN2*, *BPI*, *CD274* \[PD-L1\], *Arginase 1* \[*ARG1*\], and ANXA1).(E) Expression of *ARG1* and *CD274*(PD-L1) projected on the UMAP from (A).See also [Figure S4](#figs4){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}.Figure S4Additional Analysis of Dysfunctional Neutrophils in PBMC Fraction, Related to [Figure 5](#fig5){ref-type="fig"}A, Dot plot of marker genes associated with immature neutrophils (pro- and pre-neutrophils), and mature neutrophils.B, Pie charts showing the proportion of cells predicted to be in a given cell cycle stage. The numbers refer to the cell clusters presented in panel A.

Differential gene expression analysis for each cluster revealed extensive phenotypic heterogeneity within the LDN compartment ([Figure 5](#fig5){ref-type="fig"}B). LDNs mainly arise under pathological conditions, such as severe infection and sepsis in the context of emergency myelopoiesis ([@bib109]), and they have been associated with dysfunctional immune responses, marked by combined immunosuppression and inflammation ([@bib113]). While LDN in cluster 1 expressed numerous ISGs (*ISG15*, *IFITM1/3*, and *RSAD2*), cluster 4 (pro-neutrophils) expressed genes (e.g., *MPO*, *ELANE*, and *PRTN3*) that are involved in neutrophil extracellular trap formation ([@bib115]; [@bib119]; [@bib131]) among other functions and that have been associated with sepsis ([@bib1]; [@bib16]; [@bib113]). Both pre-neutrophil clusters expressed *PADI4*, another co-factor in NETosis ([@bib61]) ([Figure 5](#fig5){ref-type="fig"}D). NETs have recently been implicated in the pathogenesis of COVID-19 ([@bib8]; [@bib136]). Both pre-neutrophils (clusters 3 and 5) and pro-neutrophils expressed genes including *CD24*, *OLFM4*, *LCN2*, and *BPI*, previously associated with poor outcome in sepsis ([Figures 5](#fig5){ref-type="fig"}B and [S4](#figs4){ref-type="fig"}A) ([@bib50]).

All LDNs also expressed high levels of alarmins *S100A8* and *S100A9* ([Figure 5](#fig5){ref-type="fig"}D), whereas other S100 genes (e.g., *S100A4* and *S100A12*) were strongly induced in selected neutrophil clusters. Finally, known inhibitors of T cell activation, namely *CD274* (PD-L1) and *Arginase 1* (*ARG1*) ([@bib13]; [@bib62]) were highly expressed in neutrophils in COVID-19 patients ([Figure 5](#fig5){ref-type="fig"}E). *ARG1* ^*+*^ neutrophils in sepsis patients were shown to deplete arginine and constrain T cell function in septic shock ([@bib25]) and were predictive of the development of nosocomial infections ([@bib121]). Mature *CD274*(PD-L1)^+^ neutrophils (cluster 0) have been attributed suppressive functions in various conditions including HIV-1 infection ([@bib11]), cancer ([@bib21]) and in lymph nodes ([@bib18]), spleen ([@bib58]), and blood after LPS exposure ([@bib27]). *ARG1* ^*+*^ cells were mainly immature neutrophils (clusters 3--6) and did not overlap with *CD274* (PD-L1) expressing cells, indicating different populations of dysfunctional and potentially suppressive neutrophils in severe COVID-19.

LDNs recovered from PBMC fractions of COVID-19 patients revealed the presence of dysfunctional neutrophils and pointed toward multiple potentially deleterious pathways activated in severe COVID-19.

Persistent Increase of Activated Neutrophil Precursors and PD-L1^+^ Neutrophils in Severe COVID-19 {#sec2.6}
--------------------------------------------------------------------------------------------------

Alterations of the neutrophil compartment were further interrogated by mass cytometry of whole blood samples of COVID-19 patients (n = 8 mild + 9 severe, cohort 1), FLI patients (n = 8), and age- and gender-matched controls (n = 9) ([Table S1](#mmc1){ref-type="supplementary-material"}), using a panel designed to detect myeloid cell maturation and activation states as well as markers of immunosuppression or dysfunction ([Table S2](#mmc2){ref-type="supplementary-material"}). Unsupervised clustering analysis of all neutrophils in all samples revealed 10 major clusters ([Figure 6](#fig6){ref-type="fig"} A) of immature (clusters 2, 5, 6, and 7), mature (clusters 1, 3, and 4), and remaining clusters of low abundancy (clusters 8, 9, and 10). Based on their differential expression of CD11b, CD16, CD24, CD34, and CD38, clusters 5 and 6 were identified as pro-neutrophils and cluster 2 as pre-neutrophils ([@bib57]; [@bib87]). The fourth immature cell cluster (7) showed very low expression of CD11b and CD16, reminiscent of pro-neutrophils, but lacking CD34, CD38, and CD24 ([Figure 6](#fig6){ref-type="fig"}A), suggesting a hitherto unappreciated pro-neutrophil-like population. The mature neutrophils segregated into non-activated (cluster 1), partially activated (cluster 3), and highly activated cells (cluster 4), based on the loss of CD62L and upregulation of CD64, as well as signs of proliferative activity (Ki67^+^) ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Appearance of Immature and PD-L1^+^ Neutrophils in Severe COVID-19(A) Heatmap revealing differences in marker expression determined by mass cytometry (antibody panel 2, cohort 1) of main neutrophil cell cluster (1 to 10). Main individual neutrophil cell clusters are displayed in columns and marker identity is indicated in rows. MSI, marker staining intensity respective expression level. Significance level for the following comparisons: (1) controls (ctrl, n = 9) versus COVID-19 (mild and severe, n = 17, first row), (2) mild (n = 8) versus severe (n = 9, second row), (3) FLI (n = 8) versus mild COVID-19 (n = 8, third row), as well as (4) controls (ctrl, n = 9) versus FLI (n = 8) are indicated using a gray scale on top of the heatmap (see also p value scale next to the heatmap). Samples of COVID-19 patients collected between day 4 and 13 post-symptom onset (= first day of sample collection per patient). Abundance testing via generalized mixed effects models and multiple comparison adjustment using the Benjamini-Hochberg procedure and an FDR-cutoff of 5% across all clusters/subsets and between-group comparisons(B) UMAP of neutrophils, down-sampled to 70,000 cells (30 markers, [Table S2](#mmc2){ref-type="supplementary-material"}). Cells are colored according to main cell clusters (1 to 10, see table). Donor origin (blue, controls; gray, FLI; yellow, mild COVID-19; red, severe COVID-19).(C) UMAP (from (B) with cells colored according to expression intensity of CD38, CD34, CD16, CD11b, CD33, CD64, CD62L, and CD45.(D) Box and whisker (10--90 percentile) plots of main neutrophil cell clusters 1 to 7, reaching proportions of over 1%, measured by mass cytometry (whole blood, cohort 1): controls (n = 9), FLI (n = 8), and COVID-19 (mild, n = 8; severe, n = 9). Abundance testing via generalized mixed effects models and multiple comparison adjustment using the Benjamini-Hochberg procedure and an FDR-cutoff of 5% across all clusters/subsets and between-group comparisons.(E) Box and whisker (10--90 percentile) plots of proportions of CD34^+^, CD11b^lo/−^CD16^−^, CD64^+^, CD62L^+^, CD10^−^CD11b^lo/−^CD16^−^ (reported from panel 1) and PD-L1^+^ neutrophils (whole blood, cohort 1): controls (n = 9), FLI (n = 8), and COVID-19 (mild, n = 8; severe, n = 9). Kruskal-Wallis and Dunn's multiple comparison tests.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Figure S5](#figs5){ref-type="fig"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}.

Neutrophils from COVID-19 patients clearly separated from those of controls and also FLI patients in UMAP analysis ([Figure 6](#fig6){ref-type="fig"}B), and neutrophils in patients with severe COVID-19 were distinct from those of patients with mild disease ([Figure 6](#fig6){ref-type="fig"}B). Cells from control donors accumulated in areas enriched for mature non-activated cells (cluster 1) and immature pre-neutrophil-like cells (cluster 2). In contrast, neutrophils from FLI patients were mainly mature non-activated (cluster 1) and mature highly activated (cluster 4) cells. Neutrophils from COVID-19, particularly from patients with severe disease, primarily occupied immature pre- and pro-neutrophil-like clusters. Plotting cell cluster-specific surface marker expression onto the UMAPs ([Figure 6](#fig6){ref-type="fig"}C) as well as statistical analyses of cell cluster distribution and surface marker expression among different patient groups supported these observations ([Figures 6](#fig6){ref-type="fig"}D and 6E). Samples from FLI patients contain a high proportion of highly activated mature neutrophils, but barely any immature neutrophils. In contrast, severe COVID-19 is associated with the appearance of immature pre- and pro-neutrophils ([Figures 6](#fig6){ref-type="fig"}D and 6E). Interestingly, immature cell clusters in severe COVID-19 showed signs of recent activation like upregulation of CD64 ([@bib85]), RANK, and RANKL ([@bib101]), as well as reduced CD62L expression ([@bib85]). In addition to loss of CD62L, immature and mature neutrophils from severe COVID-19 showed elevated PD-L1 expression compared to control samples ([Figure 6](#fig6){ref-type="fig"}E). Indeed, CD62L downregulation and high PD-L1 expression has been frequently associated with suppressive function of neutrophils and granulocytic myeloid-derived suppressor cells (gMDSCs) ([@bib14]; [@bib17]; [@bib48]; [@bib94]; [@bib117]; [@bib118]; [@bib132]). Interestingly, a recent study described a high abundance of similar immature and dysfunctional CD64^+^ and PD-L1^+^ neutrophils in sepsis patients ([@bib76]).

Thus, SARS-CoV-2 infection induces major alterations in the neutrophil compartment. While neutrophils in FLI patients display a mature activated phenotype, a release of immature neutrophils with phenotypic signs of immunosuppression and dysfunction is a hallmark of severe COVID-19.

We next assessed the dynamics of the changes within the myeloid cell compartment over time. We grouped samples according to collection time as "early" (within the first 10 days) or late (during the following 20 days) after onset of symptoms. In both cohorts, we observed a tendency toward (cohort 1) or significantly higher (cohort 2) proportions of granulocytes in severe versus mild COVID-19 patients, both at early and late time points ([Figure S5](#figs5){ref-type="fig"} A). We observed a persistent release of immature neutrophils (e.g., cluster 6) in severe COVID-19 ([Figure S5](#figs5){ref-type="fig"}B) showing high expression of CD64 and PD-L1, but downregulation of CD62L as a sign of activation, dysfunction, and immunosuppression ([Figure S5](#figs5){ref-type="fig"}C). In addition, severe COVID-19 patients show further increased frequencies of mature, partially activated neutrophils (cluster 3) at later time periods ([Figure S5](#figs5){ref-type="fig"}B). Thus, the neutrophil compartment of severe COVID-19 patients is characterized by a combination of persistent signs of inflammation and immunosuppression, which is reminiscent of long-term post-traumatic complications ([@bib38]).Figure S5Longitudinal Analysis of Neutrophil and Monocyte Cell Populations, Related to [Figure 6](#fig6){ref-type="fig"}A, Box and whisker (10-90 percentile) plots of time-dependent differences in total granulocytes and monocytes, non-classical monocytes and correlation analysis between days post-symptom onset and proportion of non-classical monocytes.B, Box and whisker (10-90 percentile) plots of time-dependent differences in main neutrophil cell cluster 3, 5, 6 and 7 in cohort 1.C, Box and whisker (10-90 percentile) plots of time-dependent differences in proportions of CD34^+^, CD11b^lo/-^CD16^-^, CD64^+^, CD62L^+^, CD10^-^CD11b^lo/-^CD16^-^ (reported from panel 1) and PD-L1^+^ neutrophils in cohort 1.D, Box and whisker (10-90 percentile) plots of time-dependent differences in main monocyte cluster 1, 10 (belonging to CD14^hi^CD16^-^ classical monocytes), cluster 11 and 3 (belonging to CD14^hi^CD16^+^ intermediate monocytes) in cohort 1.E, Box and whisker (10-90 percentile) plots of time-dependent differences in CXCR3^+^, HLA-DR^hi^CD11c^hi^ and CD226^+^CD69^+^ monocytes.(F), Box and whisker (10-90 percentile) plot showing time-dependent differences in HLA-DR^hi^CD11c^hi^ monocytes in cohort 2.Measurements in cohort 1 were done applying mass cytometry on whole blood samples distinguishing between COVID-19 patients with mild (days 0-10: n = 6, days 11-30: n = 12) or severe disease (days 0-10: n = 9, days 11-30: n = 13) course. Mixed-effect-analysis and Sidak's multiple comparison test was used to calculate significant differencesMeasurements in cohort 2 were done with flow cytometry on 26 whole blood samples from COVID-19 patients showing either mild (n = 8) or severe disease (n = 18) course as well as 11 samples from age-matched controls (n = 10).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001

We also analyzed time-dependent phenotypic changes in the monocyte compartment by mass cytometry. Non-classical monocytes started to recover in COVID-19 patients during the later stages of the disease ([Figure S5](#figs5){ref-type="fig"}A). HLA-DR^hi^CD11c^hi^ monocyte cell clusters also declined at later time points in mild COVID-19 ([Figures S5](#figs5){ref-type="fig"}D--S5F), which correlates well with the longitudinal changes of *IFI6* and *ISG15* as well as *HLA-DRA* and *HLA-DRB1* expression profiles ([Figures 4](#fig4){ref-type="fig"}G and [S3](#figs3){ref-type="fig"}F). In contrast, overall proportions of HLA-DR^hi^CD11c^hi^ monocytes in severe COVID-19 remained low throughout the course of the disease. Proportions of CD10^hi^ macrophage-like cluster 10 and CD226^+^CD69^+^ monocytes were generally higher at later stages in severe COVID-19, which resembled the kinetics of *HLA-DR* ^*lo*^ *S100A* ^*hi*^ monocytes identified by scRNA-seq ([Figure 4](#fig4){ref-type="fig"}F). This indicates a prolonged alternative activation of monocytes in severe COVID-19 ([Figure S5](#figs5){ref-type="fig"}E).

Single-Cell Transcriptomes of Whole Blood Reveal Suppressive-like Neutrophils in Severe COVID-19 {#sec2.7}
------------------------------------------------------------------------------------------------

Whole blood CyTOF analysis (cohort 1) clearly indicated very distinct phenotypic alterations of the neutrophil compartment in mild and severe forms of COVID-19. To further delineate the underlying transcriptional programs, we performed scRNA-seq analysis on fresh whole blood samples of 23 individuals (34 samples, cohort 2, [Table S1](#mmc1){ref-type="supplementary-material"}). Integrated visualization of all samples of cohort 2 (fresh/frozen PBMCs, fresh whole blood, 229,731 cells, [Figure S6](#figs6){ref-type="fig"} A) revealed the expected blood leukocyte distribution, including granulocytes ([Figures 7](#fig7){ref-type="fig"} A and [S6](#figs6){ref-type="fig"}A; [Table S4](#mmc4){ref-type="supplementary-material"}). Cell-type distribution identified by scRNA-seq profiles ([Figure S6](#figs6){ref-type="fig"}B) strongly correlated with MCFC characterization of the same samples ([Figure S6](#figs6){ref-type="fig"}C). For further analysis of the granulocyte compartment, we first combined the whole blood samples with the fresh PBMCs to guide the clustering of all major immune cells resulting in a total of 122,954 cells ([Figure 7](#fig7){ref-type="fig"}A). From these samples, we identified all neutrophil clusters and extracted the cells derived from whole blood for subsampling, which revealed a structure of 9 clusters (n = 58,383 cells) ([Figures 7](#fig7){ref-type="fig"}B and 7C).Figure S6Overview of scRNA-Seq Dataset from Cohort 2 and Additional Characterization of Neutrophils, Related to [Figure 7](#fig7){ref-type="fig"}(A), UMAP (on the left) of the complete scRNA-seq dataset from cohort 2 (frozen PBMC, fresh PBMC, fresh whole blood), encompassing 98 samples from 16 controls, 8 mild, and 10 severe COVID-19 patients. Right panel: violin plots of the number of genic reads, transcripts and genes expressed in the PBMC (right) versus the granulocyte fraction (left) across the different datasets of cohort 2. The UMAP is split by experimental condition and the classified granulocyte and PBMC fractions are marked separately. The table below indicates the number of cells per experimental condition separated by control, COVID-19 mild and COVID-19 severe. The numbers of samples are indicated in brackets.(B), Box and whisker plots (25--75 percentile) of cell type frequencies identified by scRNA-seq in fresh whole blood samples after erythrocyte lysis comparing 16 samples from 15 controls, 6 from 5 mild COVID-19 and 12 from 4 severe COVID-19 patients.(C), Comparison between cell frequencies identified by scRNA-seq and MCFC. Pearson's correlation between the mean of each cell population measured in MCFC (y axis) and by scRNA-seq of R^2^ = 0.96 with p = 0.0098 (left). The stacked bar chart sorted by disease severity shows the cell type frequency for controls (n = 16), mild (n = 5) and severe COVID-19 samples (n = 18) split by scRNA-seq and MCFC.(D), Dot plot of literature-based marker genes classifying different neutrophil subsets.(E), UMAP of neutrophils showing the scaled expression of *MME*(CD10) and *CXCR4* with enrichment in the control-specific clusters 0.(F), UMAP of AUCell-based enrichment of gene signatures derived from the neutrophil clusters from cohort 2 on the UMAP visualization of cohort 1. The UMAP is colored by the 'Area Under the Curve' (AUC) scores of each cell.(G), Dot plot visualization of selected significantly enriched Gene Ontology terms and KEGG pathways for each cluster from the neutrophil space. The dots are colored by their adjusted p value and the size of the dots is defined by the number of genes found in the Gene Ontology term.(H), Network representation of marker genes and their predicted upstream transcriptional regulators for neutrophil clusters 6 (pre-Neutrophils) and 8 (pro-Neutrophils). Edges represent predicted transcriptional regulation. Transcription factors in the inner circle and their predicted target genes in the outer circle are represented as nodes sized and colored according to the scaled expression level across all clusters. Selected genes and transcription factors were labeled based on connectivity and literature mining.(I), Diffusion map dimensionality reduction of the main neutrophil clusters 8, 6, 2, and 1 from the severe COVID-19 patients (top) and diffusion pseudotime visualized on the diffusion map indicating the transition probability of the different clusters in the following order: 8 - 6 - 2 - 1 (bottom).(J), Genes specific for each cluster (*HSP90AA1*, *CD274*(PD-L1), *CD177*, *MME*(CD10), *ARG1*) visualized along the diffusion pseudotime (top) with the density of each cluster along the pseudotime (bottom) highlighting the proposed order of differentiation of the different neutrophil subsets.Figure 7Immature and Dysfunctional Whole-Blood Neutrophils in Severe COVID-19(A) UMAP of 35 fresh blood samples from cohort 2 (122,954 cells, PBMCs, and whole blood): controls (n = 17), mild COVID-19 (early, n = 3; late, n = 3) and severe COVID-19 (early, n = 3, late = 9). Clusters defined by Louvain clustering. Cell types assigned based on reference-based cell type classification ([@bib5]) and marker gene expression ([Table S4](#mmc4){ref-type="supplementary-material"}).(B) UMAP visualization of neutrophils (58,383 cells; 34 whole blood samples, cohort 2): controls (n = 16), mild COVID-19 (early, n = 3; late, n = 3), and severe COVID-19 (early, n = 3; late, n = 9). Clusters defined by Louvain clustering ([Table S4](#mmc4){ref-type="supplementary-material"}).(C) Nomenclature and marker genes for each neutrophil cluster from (B).(D) Dot plot of selected marker genes for each neutrophil cluster from (B).(E) Dot plot of genes from different functional classes (based on literature research). Clusters 8, 6, 1, and 2 are specific for severe COVID-19, cluster 0 represents homeostatic mature neutrophils from controls.(F) Heatmap divided by disease severity and stage (early versus late) showing the proportion of each patient group for each cluster.(G) Density plot of cell frequency by disease severity and stage (early versus late) overlaid on the UMAP of the neutrophil space.(H) UMAP visualization showing scaled expression of *CD274* (*PD-L1*) and *FCGR1A* (CD64).(I) Violin plots showing AUCell-based enrichment as AUC scores of gene signature from granulocytic myeloid-derived suppressor cells ([@bib9]) and PD-L1^hi^ neutrophils after LPS exposure ([@bib27]) in neutrophil clusters from (B). Horizontal lines: median of the respective AUC scores per cluster and 0.25 and 0.75 quantiles.(J) Network representation of marker genes and their predicted upstream transcriptional regulators for neutrophil clusters 1 (mature/COVID-19 severe-specific) and 0 (mature/control-specific). Edges in cluster color: predicted transcriptional regulation. TFs (inner circle) and their predicted target genes (outer circle): nodes, sized, and colored according to scaled expression level across all clusters. Selected genes and TFs labeled based on connectivity and literature mining.(K) Box and whisker (10-90 percentile) plots representing the hematological analyses (whole blood, cohort 1): mild (n = 11), severe (n = 21) COVID-19. Analytes, measured by flow cytometry in white blood cell differential channel, included absolute counts of immature granulocytes (IG, dotted line: upper limit of reference range) and width of neutrophil cytometric dispersions (NE-WX, dispersion of side scatter; NE-WY, dispersion of side fluorescence light; NE-WZ, dispersion of forward scatter). Mann Whitney test applied to IG count analysis and mixed-effect-analysis and Sidak's multiple comparison test to NE-WX, NE-WY, and NE-WZ analyses.(L) Box and whisker (10--90 percentile) plots of *E. coli*- and PMA-induced neutrophil oxidative burst (reactive oxygen species \[ROS\] production) and phagocytosis of whole blood samples (cohort 1; mild, n = 10; severe \[n = 8\] COVID-19) in comparison to controls measured by flow cytometry. Dotted line: relative level of controls run in the assay. Mixed-effect-analysis and Sidak's multiple comparison test. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Figure S6](#figs6){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Using marker- and data-driven approaches as applied to LDN ([Figure 5](#fig5){ref-type="fig"}D and [S4](#figs4){ref-type="fig"}A), we identified *FUT4*(CD15*)* ^*+*^ *CD63* ^*+*^ *CD66b* ^*+*^ pro-neutrophils, *ITGAM*(CD11b)^+^ *CD101* ^*+*^ pre-neutrophils, along with 7 mature neutrophil clusters ([Figures 7](#fig7){ref-type="fig"}B--7D and [S6](#figs6){ref-type="fig"}D; [Table S4](#mmc4){ref-type="supplementary-material"}). Heterogeneous expression of various markers involved in mature neutrophil function including *CXCR2*, *FCGR2A* (CD32), *FCGR1A* (CD64), or *MME* (CD10), pointed toward distinct functionalities within the neutrophil compartment ([Figures 7](#fig7){ref-type="fig"}E, [S6](#figs6){ref-type="fig"}D, and S6E). Seven of the nine neutrophil clusters identified in whole blood in cohort 2 could also be mapped to the fresh PBMC transcriptomes in cohort 1 ([Figure S6](#figs6){ref-type="fig"}F), indicating that scRNA-seq of fresh PBMC in COVID-19 patients reveals relevant parts of the neutrophil space. The transcriptional phenotype of pro- and pre-neutrophils (cluster 8+9) was corroborated in cohort 2 ([Figures 7](#fig7){ref-type="fig"}B--7D and [S6](#figs6){ref-type="fig"}D).

Heatmap and UMAP visualization of the cell type distribution identified pro- and pre-neutrophils mainly at late time points in severe COVID-19 ([Figures 7](#fig7){ref-type="fig"}F and 7G). Furthermore, mature neutrophils with a high IFN-signature (cluster 1) were associated with severe COVID-19 ([Figures 7](#fig7){ref-type="fig"}E and [S6](#figs6){ref-type="fig"}G). This cluster was also enriched for markers identified by CyTOF as differentially expressed in patients with severe COVID-19 ([Figure 6](#fig6){ref-type="fig"}), such as elevated expression of *CD274* (PD-L1) and *FCGR1A* (CD64) ([Figure 7](#fig7){ref-type="fig"}H). In addition to *CD274*, cells in cluster 1 expressed genes indicative of a potentially suppressive or anti-inflammatory state, including *ZC3H12A* ([Figure 7](#fig7){ref-type="fig"}E), which is known to suppress hepatitis C virus replication and virus-induced pro-inflammatory cytokine production ([@bib65]). Cluster 2 was also enriched for cells from COVID-19 patients, mainly from severe but also mild cases ([Figures 7](#fig7){ref-type="fig"}F and 7G).

Gene signatures from granulocytic MDSC ([@bib9]) and *CD274*(PD-L1)^+^ neutrophils after LPS exposure ([@bib27]), both shown to be immunosuppressive, were enriched in clusters 1, 2, and 6, which mainly harbor cells from severe COVID-19. This indicates a suppressive functionality of these cells in severe COVID-19 ([Figure 7](#fig7){ref-type="fig"}I). Predictions of transcription factor (TF)-based regulation of the cluster-specific gene signatures separated mature neutrophils from patients with severe COVID-19 (cluster 1) and control patients (cluster 0) ([Figure 7](#fig7){ref-type="fig"}J). IFN-response genes are mainly controlled by STAT and IRF TFs, whereas the transcriptional signature of cluster 0 is mainly driven by the CEBP TF family. The TF network underlying the transcriptional difference in pro-neutrophils is mainly driven by E2F family members and pre-neutrophils mainly depend on ETS TFs ([Figure S6](#figs6){ref-type="fig"}H).

Pseudotime analysis strongly supported the differentiation trajectory from pro-neutrophils (cluster 8) via pre-neutrophils (cluster 6) to mature neutrophils in cluster 2 and 1 ([Figures S6](#figs6){ref-type="fig"}I and S6J). Particularly *CD274* (PD-1L) was enriched in cluster 1 compared to cluster 2, supporting the potential of neutrophils to progress toward a suppressive phenotype in severe COVID-19 ([Figure S6](#figs6){ref-type="fig"}J). Interestingly, *CD177* is expressed in pre-neutrophils and persisting in cluster 1 further highlighting the newly emerging character of this cluster ([@bib125]).

Finally, we studied whether the persistent emergence of immature, potentially dysfunctional neutrophils in severe COVID-19 patients can be captured under routine diagnostic conditions. Therefore, samples of 32 COVID-19 patients ([Table S1](#mmc1){ref-type="supplementary-material"}, cohort 1) were characterized by routine hematology analyses using a clinical flow cytometry system (Sysmex analyzer). Indeed, the assumption of rescue myelopoiesis in severe COVID-19 was supported by significantly higher counts in the population of immature granulocytes (IG, representing promyelocytes, myelocytes, and metamyelocytes) in this patient group ([Figure 7](#fig7){ref-type="fig"}K). We also found significant differences in the neutrophil compartment, when analyzing the width of dispersion with respect to granularity, activity, and cell volume defined as NE-WX, NE-WY, and NE-WZ, respectively. As compared to patients with mild course, severely ill patients displayed increases in width of dispersion of activity and cell volume as surrogates for increased cellular heterogeneity, immaturity, and dysregulation in severe COVID-19 ([Figure 7](#fig7){ref-type="fig"}K), resembling previously described alterations in sepsis patients ([@bib114]). Furthermore, neutrophils of severe COVID-19 patients were partially dysfunctional, because their oxidative burst upon stimulation with standardized stimuli (*E. coli* or PMA) was strongly impaired in comparison to control and mild COVID-19 neutrophils, whereas phagocytic activity was preserved ([Figure 7](#fig7){ref-type="fig"}L; [Table S1](#mmc1){ref-type="supplementary-material"}).

Collectively, the neutrophil compartment in peripheral blood of severe COVID-19 patients is characterized by the appearance of LDN, *FUT4*(CD15)^*+*^ *CD63* ^*+*^ *CD66b* ^*+*^ pro-neutrophils, and *ITGAM*(CD11b)^+^ *CD101* ^*+*^ pre-neutrophils, reminiscent of emergency myelopoiesis, as well as *CD274*(PD-L1)^*+*^ *ZC3H12A* ^+^ mature neutrophils reminiscent of gMDSC-like cells, which might exert suppressive or anti-inflammatory functions.

Discussion {#sec3}
==========

SARS-CoV-2 infection generally causes mild disease in the majority of individuals, however, ∼10%--20% of COVID-19 patients progress to severe disease with pneumonia and respiratory failure. The reported case-fatality rates among patients with critical illness and respiratory failure vary, with a mean of ∼25% ([@bib97]). Dysregulated immune responses have been described in patients with severe COVID-19 ([@bib20]; [@bib33]; [@bib68]; [@bib80]; [@bib81]; [@bib127]; [@bib135]). Hence, detailed knowledge of the cellular and molecular processes that drive progression from mild disease to potentially fatal courses of COVID-19 is urgently needed to identify predictive biomarkers and therapeutic targets.

Here, we employed four complementary technologies at single-cell resolution to assess alterations in the systemic immune response in mild or severe courses of COVID-19. We analyzed a total of 53 patients (161 samples) from two independent cohorts collected at two university medical centers in Germany ([@bib55]). Combining single-cell transcriptomics with single-cell proteomics, using different technological platforms in two independent patient cohorts, provided a detailed view of the systemic immune responses in COVID-19 and allowed for cross-validation and in-depth interrogation of key findings. The results were further supported by additional routine diagnostics lab measurements and functional assays, linking the results of the exploratory investigations to functional phenotypes and clinically relevant diagnostics.

This multipronged approach revealed drastic changes within the myeloid cell compartment during COVID-19, particularly in patients with a severe course of disease. Early activation of HLA-DR^hi^CD11c^hi^/*HLA-DR* ^*hi*^ *CD83* ^*hi*^ monocytes with a strong antiviral IFN-signature was a hallmark of mild COVID-19, which receded during the natural course of disease. In contrast, HLA-DR^lo^ dysfunctional monocytes along with clear evidence of emergency myelopoiesis with release of immature neutrophils including pro- and pre-neutrophils into the circulation marked severe COVID-19. Furthermore, we identified neutrophils in severe COVID-19 with transcriptional programs reminiscent of dysfunction and immunosuppression not observed in controls or patients with mild COVID-19. Thus, defective monocyte activation and dysregulated myelopoiesis may contribute to severe disease course and ARDS development ([@bib83]).

Previous immunophenotyping studies have reported an increase of inflammatory monocytes with a strong IFN-response in COVID-19 ([@bib63]; [@bib80]; [@bib135]). Mononuclear phagocytes and neutrophils appear to dominate inflammatory infiltrates in the lungs, and resident alveolar macrophages are replaced by inflammatory monocyte-derived macrophages in patients with severe COVID-19 ([@bib20]; [@bib63]). Here, we report substantial time- and disease severity-dependent alterations of the monocyte compartment in COVID-19. Marked depletion of CD14^lo^CD16^hi^ non-classical monocytes observed in all COVID-19 patients, but not in patients with SARS-CoV-2 negative FLI ([Figure 1](#fig1){ref-type="fig"}D), is in line with previous reports on COVID-19, and other severe viral infections ([@bib69]; [@bib86]). Single-cell proteomics and transcriptomics revealed a transient increase in highly activated CD14^+^HLA-DR^hi^CD11c^hi^ (*HLA-DRA* ^*hi*^ *CD83* ^*hi*^) monocytes in mild COVID-19. This was similar in patients presenting with common cold or FLI, but absent in severe COVID-19 ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). In contrast, in severe COVID-19, monocytes showed low expression of HLA-DR, and high levels of *MAFB*, *PLBD1*, and *CD163*, all of which are associated with anti-inflammatory macrophage functions ([@bib14]; [@bib24]; [@bib32]; [@bib70]). Low HLA-DR expression on monocytes is an established surrogate marker of immunosuppression in sepsis ([@bib123]). Elevated HLA-DR^lo^ monocytes have been associated with an increased risk of infectious complications after trauma ([@bib40]) and fatal outcome in septic shock ([@bib84]). Indeed, the *HLA-DR* ^*lo*^ *CD163* ^*+*^ monocytes showed enrichment of genes associated with poor prognosis in sepsis patients, including *PLAC8* ([@bib73]) and *MPO* ([@bib108]) ([Figure 4](#fig4){ref-type="fig"}B). In line with this dysfunctional phenotype, *PLAC8* was recently shown to suppress production of IL-1β and IL-18 ([@bib112]). In fact, we observed that inflammatory cytokine production, including IL-1β release, was impaired in monocytes from patients with severe COVID-19 ([Figure 4](#fig4){ref-type="fig"}). CD14^+^HLA-DR^lo^ monocytes have also been implicated with immunosuppression in cancer patients ([@bib14]; [@bib79]; [@bib82]). While exhibiting anti-inflammatory features, especially in the early stages of severe disease ([Figures S3](#figs3){ref-type="fig"}C--S3F), persistently high expression of CD226 and CD69 may promote tissue infiltration and organ dysfunction ([@bib26]; [@bib100]; [@bib124]).

Acute pathological insults, such as trauma or severe infections, trigger a process referred to as emergency myelopoiesis to replenish functional granulocytes and other hematopoietic cells. Emergency myelopoiesis is characterized by the mobilization of immature myeloid cells, which are often linked to immunosuppressive functions ([@bib66]; [@bib109]). In fact, emergence of suppressive myeloid cells including neutrophils, often referred to as granulocytic MDSCs, has been observed during sepsis and severe influenza ([@bib25]; [@bib66]; [@bib105]; [@bib28]). LDN in PBMC fractions in severe COVID-19 contained immature neutrophils, including pro- and pre-neutrophils, which was not observed in mild cases ([Figure 5](#fig5){ref-type="fig"}). These immature LDNs showed a surface marker and gene expression profile reminiscent of granulocytic MDSCs including genes such as *S100A12*, *S100A9*, *MMP8*, *ARG1* ([@bib121]), and *OLFM4*, which has been recently associated with immunopathogenesis in sepsis ([@bib3]). Emergence of pro-neutrophils in severe COVID-19 was also detected by single-cell proteomics on whole blood samples. Strikingly, both immature and the mature neutrophils showed increased expression of CD64 and PD-L1 ([Figures 6](#fig6){ref-type="fig"} and [S5](#figs5){ref-type="fig"}), similar to recently described alterations in sepsis ([@bib76]). In addition to the altered phenotype, we also observed an altered functionality. Neutrophils from patients with severe COVID-19 showed an impaired oxidative burst response, while their phagocytic capacity was preserved ([Figure 7](#fig7){ref-type="fig"}).

Single-cell transcriptomics of whole blood samples revealed mature activated neutrophils in both mild and severe COVID-19 ([Figure 7](#fig7){ref-type="fig"}B, cluster 2), however, expression of *CD274* (PD-L1) was only found in severe COVID-19 (cluster 1), and it increased in later stages of the disease. Expression of PD-L1 on neutrophils has been associated with T cell suppression ([@bib11]; [@bib18]; [@bib27]; [@bib58]), suggesting that neutrophils in severe COVID-19 might exert suppressive functions. Furthermore, the expression of *CD177* on mature activated neutrophils and the identification of genes associated with anti-inflammatory functions (*CD274* and *ZC3H12A*) suggest a model in which neutrophils emerging prematurely from the bone marrow are programmed toward an anti-inflammatory or even suppressive phenotype in severe COVID-19. The transcriptional programs induced in immature neutrophils, including pro- and pre-neutrophils, as well as in COVID-19-associated mature neutrophil clusters, align with other observations in severe COVID-19 patients, including increased NET formation ([@bib8]; [@bib136]), coagulation ([@bib51]; [@bib93]), and immunothrombosis ([@bib115]; [@bib130]). In contrast, these transcriptional programs were not observed in patients with mild COVID-19 or in SARS-CoV-2 negative controls, even though the latter exhibited a range of comorbidities (e.g., COPD, type II diabetes).

Thus, defective or repressed monocyte activation combined with dysregulated myelopoiesis may cause a deleterious loop of continuous tissue inflammation and ineffective host defense.

Limitations of Study {#sec3.1}
--------------------

The pathophysiological consequences of the dysfunctional phenotype of myeloid cells in severe COVID-19 remain unclear at this stage. It is, however, highly likely that they contribute to immunosuppression in critically ill patients, potentially leading to insufficient host defense, disbalanced inflammation, and increased susceptibility to superinfections. While our dual cohort study design provided robust and reproducible results concerning the alterations within the myeloid compartment in COVID-19, it is too early to speculate on the underlying mechanisms driving this response, such as genetics, lifestyle, comorbidities, environmental factors, or initial viral load ([@bib31]). Utilizing the herein established transcriptional and functional phenotypes of the myeloid cell compartment, it will likely be possible to estimate the potential contribution of the causes mentioned above in larger clinical studies in the future and to address potential upstream events of immune dysregulation in preclinical model systems as they become available ([@bib7]; [@bib23]). Indeed, in future studies it will be interesting to dissect whether the myeloid subsets in COVID-19 are anti-inflammatory or even capable of suppressing other immune cells, and which pathways might be mainly involved. Clearly, PD-L1 is a prime candidate ([@bib11]; [@bib18]; [@bib27]; [@bib58]).

Collectively, our data link a striking appearance of immature and dysfunctional cells, in both the monocyte and neutrophil compartment, to disease severity in COVID-19. Consequently, the development of treatments and prevention strategies for severe COVID-19 may benefit from insights gained in other fields such as oncology, which have successfully applied therapies targeting suppressive myeloid cells.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**HLA-DR BV421 (L243)BiolegendCat\# 307635; RRID:[AB_10897449](nif-antibody:AB_10897449){#intref0010}CD4 BV510 (OKT4)BiolegendCat\# 317444; RRID:[AB_2561866](nif-antibody:AB_2561866){#intref0015}CD16 BV605 (3G8)BiolegendCat\# 302039; RRID:[AB_2561354](nif-antibody:AB_2561354){#intref0020}CD45 BV711 (HI30)BiolegendCat\# 304050; RRID:[AB_2563466](nif-antibody:AB_2563466){#intref0025}CD8 BV785 (SK1)BiolegendCat\# 344740; RRID:[AB_2566202](nif-antibody:AB_2566202){#intref0030}CD66b FITC (G10F5)BiolegendCat\# 305104; RRID:[AB_314496](nif-antibody:AB_314496){#intref0035}CD14 PerCp-Cy5.5 (MφP9)Becton DickinsonCat\# 562692; RRID:[AB_2737726](nif-antibody:AB_2737726){#intref0040}CD56 PE (MY31)Becton DickinsonCat\# 345810; RRID:[AB_396511](nif-antibody:AB_396511){#intref0045}CD3 PE/Dazzle (UCHT1)BiolegendCat\# 300450; RRID:[AB_2563618](nif-antibody:AB_2563618){#intref0050}CD11c PE/Cy5 (B-ly6)Becton DickinsonCat\# 551077; RRID:[AB_394034](nif-antibody:AB_394034){#intref0055}Siglec8 PE/Cy7 (7C9)BiolegendCat\# 347112; RRID:[AB_2629720](nif-antibody:AB_2629720){#intref0060}CD203c APC (NP4D6)BiolegendCat\# 324609; RRID:[AB_2099774](nif-antibody:AB_2099774){#intref0065}CD1c AlexaFluor700 (L161)BiolegendCat\# 331530; RRID:[AB_2563657](nif-antibody:AB_2563657){#intref0070}CD19 APC/Fire 750 (HIB19)BiolegendCat\# 302258; RRID:[AB_2629691](nif-antibody:AB_2629691){#intref0075}CD45 89Y (HI30)FluidigmCat\# 3089003; RRID:[AB_2661851](nif-antibody:AB_2661851){#intref0080}HLA-DR purified (L243)BiolegendCat\# 307602; RRID:[AB_314680](nif-antibody:AB_314680){#intref0085}CD3 purified (UCHT1)BiolegendCat\# 300443; RRID:[AB_2562808](nif-antibody:AB_2562808){#intref0090}CD196 141Pr (G034E3)FluidigmCat\# 3141003A; RRID:[AB_2687639](nif-antibody:AB_2687639){#intref0095}CD19 142Nd (HIB-19)FluidigmCat\# 3142001; RRID:[AB_2651155](nif-antibody:AB_2651155){#intref0100}CD123 143Nd (6H6)FluidigmCat\# 3143014B; RRID:[AB_2811081](nif-antibody:AB_2811081){#intref0105}CD15 144Nd (W6D3)FluidigmCat\# 3144019BCD138 145Nd (DL101)FluidigmCat\# 3145003BCD64 146Nd (10.1)FluidigmCat\# 3146006; RRID:[AB_2661790](nif-antibody:AB_2661790){#intref0110}CD21 purified (Bu32)BiolegendCat\# 354902; RRID:[AB_11219188](nif-antibody:AB_11219188){#intref0115}CD226 purified (REA1040)Miltenyi BiotecProduced at requestIgD purified (IgD26)BiolegendCat\# 348235; RRID:[AB_2563775](nif-antibody:AB_2563775){#intref0120}ICOS 148Nd (C398.4A)FluidigmCat\# 3148019B; RRID:[AB_2756435](nif-antibody:AB_2756435){#intref0125}CD206 purified (152)BiolegendCat\# 321127; RRID:[AB_2563729](nif-antibody:AB_2563729){#intref0130}CD96 purified (REA195)Miltenyi BiotecProduced at requestKLRG1 purified (REA261)Miltenyi BiotecProduced at requestTCRgd purified (11F2)Miltenyi BiotecProduced at requestFceRI 150Nd (AER-37)FluidigmCat\# 3150027BCD155 purified (REA1081)Miltenyi BiotecProduced at requestCD95 purified (DX2)BiolegendCat\# 305631; RRID:[AB_2563766](nif-antibody:AB_2563766){#intref0135}TIGIT 153Eu (MBSA43)FluidigmCat\# 3153019B; RRID:[AB_2756419](nif-antibody:AB_2756419){#intref0140}CD62L 153Eu (DREG56)FluidigmCat\# 3153004B; RRID:[AB_2810245](nif-antibody:AB_2810245){#intref0145}CD62L purified (DREG56)BiolegendCat\# 304835; RRID:[AB_2563758](nif-antibody:AB_2563758){#intref0150}CD1c purified (L161)BiolegendCat\# 331502; RRID:[AB_1088995](nif-antibody:AB_1088995){#intref0155}CD27 155Gd (L128)FluidigmCat\# 3155001B; RRID:[AB_2687645](nif-antibody:AB_2687645){#intref0160}CXCR3 156Gd (G025H7)FluidigmCat\# 3156004B; RRID:[AB_2687646](nif-antibody:AB_2687646){#intref0165}KLRF1 purified (REA845)Miltenyi BiotecProduced at requestCD10 158Gd (HI10a)FluidigmCat\# 3158011BCD33 158Gd (WM53)FluidigmCat\# 3158001; RRID:[AB_2661799](nif-antibody:AB_2661799){#intref0170}CD14 160Gd (RMO52)FluidigmCat\# 3160006; RRID:[AB_2661801](nif-antibody:AB_2661801){#intref0175}CD28 purified (L293)BD BioscienceCat\# 348040; RRID:[AB_400367](nif-antibody:AB_400367){#intref0180}CD69 162Dy (FN50)FluidigmCat\# 3162001BCD294 163Dy (BM16)FluidigmCat\# 3163003B; RRID:[AB_2810253](nif-antibody:AB_2810253){#intref0185}RANKL APCMiltenyi BiotecCat\# 130-098-511; RRID:[AB_2656691](nif-antibody:AB_2656691){#intref0190}Anti-APC 163DyFluidigmCat\# 3163001B; RRID:[AB_2687636](nif-antibody:AB_2687636){#intref0195}CXCR5 164Dy (51505)FluidigmCat\# 3164016B; RRID:[AB_2687858](nif-antibody:AB_2687858){#intref0200}Siglec 8 164Dy (7C9)FluidigmCat\# 3164017BCD34 166Er (581)FluidigmCat\# 3166012B; RRID:[AB_2756424](nif-antibody:AB_2756424){#intref0205}CD38 167Er (HIT2)FluidigmCat\# 3167001B; RRID:[AB_2802110](nif-antibody:AB_2802110){#intref0210}Ki67 168Er (Ki-67)FluidigmCat\# 3168007B; RRID:[AB_2800467](nif-antibody:AB_2800467){#intref0215}CD25 169Tm (2A3)FluidigmCat\# 3169003; RRID:[AB_2661806](nif-antibody:AB_2661806){#intref0220}CD24 169Tm (ML5)FluidigmCat\# 3169004B; RRID:[AB_2688021](nif-antibody:AB_2688021){#intref0225}Lag3 purified (11C3C65)BiolegendCat\# 369302; RRID:[AB_2616876](nif-antibody:AB_2616876){#intref0230}RANK purified (80704)R&D SystemsCat\# MAB683; RRID:[AB_2205330](nif-antibody:AB_2205330){#intref0235}CD161 purified (HP-3G10)BiolegendCat\# 339919; RRID:[AB_2562836](nif-antibody:AB_2562836){#intref0240}CD11b purified (ICRF44)BiolegendCat\# 301337; RRID:[AB_2562811](nif-antibody:AB_2562811){#intref0245}CD45RO purified (4G11)DRFZ BerlinN/ACD44 purified (BJ18)BiolegendCat\# 338811; RRID:[AB_2562835](nif-antibody:AB_2562835){#intref0250}CD137 173Yb (4B4-1)FluidigmCat\# 3173015BPD-1 175Lu (EH12.2H7)FluidigmCat\# 3175008; RRID:[AB_2687629](nif-antibody:AB_2687629){#intref0255}PD-L1 175Lu (29.E2A3)FluidigmCat\# 3175017B; RRID:[AB_2687638](nif-antibody:AB_2687638){#intref0260}CD56 176Yb (NCAM16.2)FluidigmCat\# 3176008; RRID:[AB_2661813](nif-antibody:AB_2661813){#intref0265}CD8A purified (GN11)DRFZ BerlinN/AIgM purified (MHM-88)BiolegendCat\# 314502; RRID:[AB_493003](nif-antibody:AB_493003){#intref0270}CD11c purified (Bu15)BiolegendCat\# 337221; RRID:[AB_2562834](nif-antibody:AB_2562834){#intref0275}B2M purified (2M2)BiolegendCat\# 316302; RRID:[AB_492835](nif-antibody:AB_492835){#intref0280}CD16 209Bi (3G8)FluidigmCat\# 3209002B; RRID:[AB_2756431](nif-antibody:AB_2756431){#intref0285}A0251 anti-human Hashtag 1BiolegendCat\# 394601; RRID:[AB_2750015](nif-antibody:AB_2750015){#intref0290}A0252 anti-human Hashtag 2BiolegendCat\# 394603; RRID:[AB_2750016](nif-antibody:AB_2750016){#intref0295}A0253 anti-human Hashtag 3BiolegendCat\# 394605; RRID:[AB_2750017](nif-antibody:AB_2750017){#intref0300}A0254 anti-human Hashtag 4BiolegendCat\# 394607; RRID:[AB_2750018](nif-antibody:AB_2750018){#intref0305}A0255 anti-human Hashtag 5BiolegendCat\# 394609; RRID:[AB_2750019](nif-antibody:AB_2750019){#intref0310}A0256 anti-human Hashtag 6BiolegendCat\# 394611; RRID:[AB_2750020](nif-antibody:AB_2750020){#intref0315}A0257 anti-human Hashtag 7BiolegendCat\# 394613; RRID:[AB_2750021](nif-antibody:AB_2750021){#intref0320}CD235ab Biotin (HIR2)BiolegendCat\# 306618; RRID:[AB_2565773](nif-antibody:AB_2565773){#intref0325}**Chemicals, Peptides, and Recombinant Proteins**BD Horizon Brilliant Stain BufferBecton DickinsonCat\# 563794RBC lysis buffer 10XBiolegendCat\# 420301Pierce 16% Formaldehyde (w/v), Methanol-freeThermo FisherCat\# 28908RPMI 1640 MediumGIBCOCat\# 11875093Fetal Bovine SerumPAN BiotecCat\# 3302Stain Buffer (FBS)Becton DickinsonCat\# 554656Pancoll human, Density: 1.077 g/mlPan BiotechCat\# P04-601000Dulbecco'S Phosphate Buffered Saline, MOSigma-AldrichCat\# D8537FcR Blocking Reagent, humanMiltenyiCat\# 130-059-901Cell-ID Intercalator-IrFluidigmCat\# 201192APermeabilization buffer 10XeBioscienceCat\# 00-8333-56Maxpar PBSFluidigmCat\# 201058Maxpar Cell Staining bufferFluidigmCat\# 201068Maxpar X8 Multimetal Labeling KitFluidigmCat\# 201300Proteomic stabilizerSmart Tube Inc.Cat\# PROT1Nuclease-Free WaterInvitrogenCat\# AM9937KAPA HiFi HotStart Ready MixRocheCat\# KK2601Human Tru Stain FcXBiolegendCat\# 422301TE Buffer, pH8.0, 1mM disodium EDTAThermo FisherCat\# 12090015SPRIselectBeckmann CoulterCat\# B2331810% Tween 20BIO-RADCat\# 1662404Buffer EBQIAGENCat\# 19086Ethanol, AbsoluteFisher BioreagentsCat\# BP2818-500Glycerol, 85%MerckCat\# 1040941000Bovine Serum Albumin (IgG-Free, Protease-Free)Jackson Immuno ResearchCat\# 001-000-161LPS, TLRpureInnaxonCat\# IAX-100-010Tween20Sigma-AldrichCat\# P1379-500MMagniSort^TM^ Negative Selection BeadsThermo FisherCat\# MSNB-6002-74Lysercell WDFSysmexCat\# AL-337-564Fluorocell^TM^ WDFSysmexCat\# CV-377-552**Critical Commercial Assays**LIVE/DEAD Fixable Yellow Dead Cell Stain KitThermo FisherCat\# L34967LEGENDplex^TM^ Human Inflammation Panel 1 (Mix&Match)BiolegendCat\# 740809Human Single-Cell Multiplexing KitBecton DickinsonCat\# 633781BD Rhapsody WTA Amplification KitBecton DickinsonCat\# 633801BD Rhapsody Cartridge KitBecton DickinsonCat\# 633733BD Rhapsody cDNA KitBecton DickinsonCat\# 633773High Sensitivity D5000 ScreenTapeAgilentCat\# 5067-5592Qubit dsDNA HS Assay KitThermoFisherCat\# Q32854Chromium Next GEM Single Cell 3′ GEM, Library & Gel Bead Kit v3.110x genomicsCat\# 1000121Chromium Next GEM Chip G Single Cell Kit10x genomicsCat\# 1000120Single Index Kit T Set A10x genomicsCat\# 1000213High Sensitivity DNA KitAgilentCat\# 5067-4626NovaSeq 6000 S1 Reagent Kit (100 cycle)IlluminaCat\# 200012865NovaSeq 6000 S2 Reagent Kit (100 cycle)IlluminaCat\# 20012862NovaSeq 6000 S2 Reagent Kit (200 cycles)IlluminaCat\# 20040326NovaSeq 6000 S2 Reagent Kit (200 cycles)IlluminaCat\# 20040326NextSeq 500/550 High Output Kit v2.5 (150 Cycles)IlluminaCat\# 20024907Pan Monocyte Isolation Kit, humanMiltenyiCat\# 130-096-537CE/IVD PhagoburstBD BiosciencesCat\# 341058CD/IVD PHAGOTESTBD BiosciencesCat\# 341060**Deposited Data**scRNA-seq raw dataThis paperEGAS00001004571Processed scRNA-seq count data and codeThis paper<http://fastgenomics.org>Supplemental [Table S1](#mmc1){ref-type="supplementary-material"}, [Table S2](#mmc2){ref-type="supplementary-material"}, [Table S3](#mmc3){ref-type="supplementary-material"}, [Table S4](#mmc4){ref-type="supplementary-material"}This paper<https://data.mendeley.com/datasets/hwxhw2sxys/1>**Oligonucleotides**SI-PCR primerIDTAATGATACGGCGACCACCGAGATCTA\
CACTCTTTCCCTACACGACGC^∗^T^∗^CHTO additive primerIDTGTGACTGGAGTTCAGACGTGTGC^∗^T^∗^CD701_SIDTCAAGCAGAAGACGGCATACGAGA\
TCGAGTAATGTGACTGGAGTTCAGACGTGT^∗^G^∗^CD702_SIDTCAAGCAGAAGACGGCATACGAGA\
TTCTCCGGAGTGACTGGAGTTCAGACGTGT^∗^G^∗^CD703_SIDTCAAGCAGAAGACGGCATACGAGATA\
ATGAGCGGTGACTGGAGTTCAGACGTGT^∗^G^∗^CD705_SIDTCAAGCAGAAGACGGCATACGAGATTTC\
TGAATGTGACTGGAGTTCAGACGTGT^∗^G^∗^C**Software and Algorithms**CellRanger10x genomicsv3.1.0Bcl2fastq2Illuminav2.20STAR[@bib30]v2.6.1bCutadapt[@bib72]v1.16Dropseq-tools<https://github.com/broadinstitute/Drop-seq/>v2.0.0R<https://www.cran.r-project.org>v3.6.2Seurat (R package)[@bib15]; [@bib37]; [@bib116]v3.1.4, v3.1.2 (CRAN)Harmony (R package)[@bib52] (<https://github.com/immunogenomics/harmony>)v1.0Destiny (R package)[@bib4]v 3.0.1ClusterProfiler (R package)[@bib133]v3.10.1 (CRAN)SingleR (R package)[@bib5]v1.0.5 (Bioconductor)DirichletReg (R package)[@bib71]v0.6.3.1 (CRAN)AUCell (R package)[@bib2]v1.6.1 (CRAN)Cytobank[@bib53]<https://www.cytobank.org><https://doi.org/10.1002/0471142956.cy1017s53>SPADE (Cytobank)[@bib96]Cytobank is running a version of SPADE derived from v1.10.2flowCore (R package)<https://www.bioconductor.org/packages/release/bioc/html/flowCore.html>v1.48.1 (Bioconductor), 10.18129/B9.bioc.flowCoreCytoML (R package)<https://github.com/RGLab/CytoML>v1.8.1 (Bioconductor), 10.18129/B9.bioc.CytoMLCytofBatchAdjust (R package)<https://github.com/CUHIMSR/CytofBatchAdjust><https://doi.org/10.3389/fimmu.2019.02367>uwot (R package)<https://cran.r-project.org/web/packages/uwot/index.html>v0.1.8 (CRAN)ComplexHeatmap (R package)[@bib35]v1.20.0 (Bioconductor)lme4 (R package)[@bib89]v1.1-21 (CRAN)multcomp (R package)[@bib42]v1.4-13 (CRAN)lsmeans (R package)[@bib60]v2.30-0 (CRAN)Prism (software)<https://www.graphpad.com>v8FlowJo<https://www.flowjo.com>v10.6.1Cytoscape<https://www.cytoscape.org>v3.7.1 ([https://doi.org/10.1101/gr.1239303](10.1101/gr.1239303){#intref0405})iRegulon[@bib46]v1.3

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Joachim L. Schultze (<j.schultze@uni-bonn.de>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

ScRNA-seq data generated during this study are deposited at the European Genome-phenome Archive (EGA) under access number EGAS00001004571, which is hosted by the EBI and the CRG.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Samples from patients with COVID-19 were collected within two cohort studies ([@bib55]) designed to allow deep molecular and immunological transcriptomic and proteomic profiling of COVID-19 in blood. Patients for which sufficient material was available for scRNA-seq, CyTOF or flow cytometry analysis, were included in this study. This study was designed to describe immunological deviations in COVID-19 patients without intention of the development of new treatments or new diagnostics, and therefore sample size estimation was not included in the original study design.

### Cohort 1 / Berlin cohort {#sec4.3.1}

This study includes a subset of patients enrolled between March 2 and July 02 2020 in the Pa-COVID-19 study, a prospective observational cohort study assessing pathophysiology and clinical characteristics of patients with COVID-19 at Charité Universitätsmedizin Berlin ([@bib55]). The study is approved by the Institutional Review board of Charité (EA2/066/20). Written informed consent was provided by all patients or legal representatives for participation in the study. The patient population included in all analyses of cohort 1 consists of 10 control donors (samples collected in 2019 before SARS-CoV2 outbreak), 8 patients presenting with flu-like illness but tested SARS-CoV-2-negative, 25 mild and 29 severe COVID-19 patients ([Figures 1](#fig1){ref-type="fig"}A and 1B; [Table S1](#mmc1){ref-type="supplementary-material"}). Information on age, sex, medication, and co-morbidities is listed in [Table S1](#mmc1){ref-type="supplementary-material"}. All COVID-19 patients were tested positive for SARS-CoV-2 RNA in nasopharyngeal swabs and allocated to mild (WHO 2-4) or severe (5-7) disease according to the WHO clinical ordinal scale. We also included publicly available single-cell transcriptome data derived from 22 control samples into the analysis; 3 samples were derived from 10x Genomics, San Francisco, CA 94111, USA (5k_pbmc_v3: <https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k_pbmc_v3>, pbmc_10k_v3: <https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/pbmc_10k_v3>, pbmc_1k_v3: <https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/pbmc_1k_v3>), 19 samples derived from [@bib99]).

### Cohort 2 / Bonn cohort {#sec4.3.2}

This study was approved by the Institutional Review board of the University Hospital Bonn (073/19 and 134/20). After providing written informed consent, 19 control donors and 22 COVID-19 patients ([Figures 1](#fig1){ref-type="fig"}A and 1B; [Table S1](#mmc1){ref-type="supplementary-material"}) were included in the study. In patients who were not able to consent at the time of study enrollment, consent was obtained after recovery. Information on age, sex, medication, and co-morbidities are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. COVID-19 patients who tested positive for SARS-CoV-2 RNA in nasopharyngeal swabs were recruited at the Medical Clinic I of the University Hospital Bonn between March 30 and June 17, 2020 and allocated to mild (WHO 2-4) or severe (5-7) disease according to the WHO clinical ordinal scale. Controls in cohort 2 were collected from healthy people or from otherwise hospitalized patients with a wide range of diseases and comorbidities including chronic inflammatory immune responses. These individuals were either tested negative for SARS-CoV-2, serologically negative or had no indication for acute COVID-19 disease based on clinical or laboratory parameters.

Method Details {#sec4.4}
--------------

### Isolation of blood cells for scRNA-seq {#sec4.4.1}

#### Cohort 1 / Berlin cohort {#sec4.4.1.1}

PBMC were isolated from heparinized whole blood by density centrifugation over Pancoll (density: 1.077 g/ml; PAN-Biotech). If the pellet was still slightly red, remaining CD235ab^+^ cells (Erythrocytes) were depleted by Negative Selection (*MagniSort* Thermo Fisher). Subsequently the PBMC were prepared for 3′scRNA-seq (10xGenomics) or cryopreserved and analyzed later.

### Cohort 2 / Bonn cohort {#sec4.4.2}

In the Bonn cohort, scRNA-seq was performed on fresh whole blood, fresh PBMC and frozen PBMC. Briefly, PBMC were isolated from EDTA-treated or heparinized peripheral blood by density centrifugation over Pancoll or Ficoll-Paque density centrifugation (density: 1.077 g/ml). Cells were then washed with DPBS, directly prepared for scRNA-seq (BD Rhapsody) or cryopreserved in RPMI1640 with 40% FBS and 10% DMSO. Whole blood was prepared by treatment of 1ml peripheral blood with 10ml of RBC lysis buffer (Biolegend). After one wash in DPBS cells were directly processed for scRNA-seq (BD Rhapsody) or multi-color flow cytometry (MCFC). Frozen PBMC were recovered by rapidly thawing frozen cell suspensions in a 37°C water bath followed by immediate dilution in pre-warmed RPMI-1640+10% FBS (GIBCO) and centrifugation at 300 g for 5min. After centrifugation, the cells were resuspended in RPMI-1640+10% FBS and processed for scRNA-seq. Antibody cocktails were cryopreserved as described before ([@bib110]).

### Antibodies used for mass cytometry {#sec4.4.3}

All anti-human antibodies pre-conjugated to metal isotopes were obtained from Fluidigm Corporation (San Francisco, US). All remaining antibodies were obtained from the indicated companies as purified antibodies and in-house conjugation was done using the MaxPar X8 labeling kit (Fluidigm). [Table S2](#mmc2){ref-type="supplementary-material"} shows a detailed list of all antibodies used for panel 1 and panel 2.

### Sample processing, antigen staining and data analysis of mass cytometry-based immune cell profiling {#sec4.4.4}

500μl of whole blood (heparin) was fixed in 700μl of proteomic stabilizer (Smart Tube Inc., San Carlos, US) as described in the user manual and stored at −80°C until further processing. Whole blood samples were thawed in Thaw/Lyse buffer (Smart Tube Inc.). For barcoding antibodies recognizing human beta-2 microglobulin (B2M) were conjugated in house to ^104^Pd, ^106^Pd, ^108^Pd, ^110^Pd, ^198^Pt ([@bib77], [@bib78]; [@bib110]). Up to 10 individual samples were stained using a staining buffer from Fluidigm with a combination of two different B2M antibodies for 30min at 4°C. Cells were washed and pooled for surface and intracellular staining.

For surface staining the barcoded and pooled samples were equally divided into two samples. Cells were resuspended in antibody staining cocktails for panel 1 or panel 2 respectively ([Table S2](#mmc2){ref-type="supplementary-material"}) and stained for 30min at 4°C. For secondary antibody staining of panel 2, cells were washed and stained with anti-APC ^163^Dy for 30min at 4°C. After surface staining cells were washed with PBS and fixed overnight in PFA solution diluted in PBS to 2%.

For intracellular staining cells were washed twice with a permeabilization buffer (eBioscience, San Diego, US) and stained with the respective antibodies diluted in a permeabilization buffer for 30min at room temperature. After washing, cells were stained with iridium intercalator (Fluidigm) diluted in 2% PFA for 20min at room temperature. Cells were washed once with PBS and then twice with ddH~2~O and kept at 4°C until mass cytometry measurement.

A minimum of 100,000 cells per sample and panel were acquired on a CyTOF2/Helios mass cytometer (Fluidigm). For normalization of the fcs files 1:10 EQ Four Element Calibration Beads (Fluidigm) were added. Cells were analyzed using a CyTOF2 upgraded to Helios specifications, with software version 6.7.1014, using a narrow bore injector. The instrument was tuned according to the manufacturer's instructions with tuning solution (Fluidigm) and measurement of EQ four element calibration beads (Fluidigm) containing 140/142Ce, 151/153Eu, 165Ho and 175/176Lu served as a quality control for sensitivity and recovery. Directly prior to analysis, cells were resuspended in ddH2O, filtered through a 20-μm cell strainer (Celltrics, Sysmex), counted and adjusted to 5-8 x10^5^ cells/ml. EQ four element calibration beads were added at a final concentration of 1:10 v/v of the sample volume to be able to normalize the data to compensate for signal drift and day-to-day changes in instrument sensitivity. Samples were acquired with a flow rate of 300-400 events/s. The lower convolution threshold was set to 400, with noise reduction mode turned on and cell definition parameters set at event duration of 10-150 pushes (push = 13μs). The resulting flow cytometry standard (FCS) files were normalized and randomized using the CyTOF software's internal FCS-Processing module on the non-randomized ('original') data. The default settings in the software were used with time interval normalization (100 s/minimum of 50 beads) and passport version 2. Intervals with less than 50 beads per 100 s were excluded from the resulting FCS file.

### Blood processing for multi-color flow cytometry {#sec4.4.5}

1ml of fresh blood from control or COVID-19 donors was treated with 10ml of RBC lysis buffer (Biolegend). After RBC lysis, cells were washed with DPBS and 1-2 million cells were used for flow cytometry analysis. Cells were then stained for surface markers ([Table S3](#mmc3){ref-type="supplementary-material"}) in DPBS with BD Horizon Brilliant Stain Buffer (Becton Dickinson) for 30min at 4°C. To distinguish live from dead cells, the cells were incubated with LIVE/DEAD Fixable Yellow Dead Cell Stain Kit (1:1000 -- Thermo Scientific). Following staining and washing, the cell suspension was fixed with 4% PFA for 5min at room temperature to prevent any possible risk of contamination during acquisition of the samples. Flow cytometry analysis was performed on a BD Symphony instrument (Becton Dickinson) configured with 5 lasers (UV, violet, blue, yellow-green, red).

### *Ex vivo* functional analysis of neutrophils {#sec4.4.6}

Determination of neutrophil oxidative burst and phagocytosis was performed by flow cytometry using the CE/IVD PHAGOBURST and PHAGOTEST assay (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions.

Briefly, heparinized whole blood was incubated with PMA, unlabeled opsonized *E. coli* bacteria or washing solution (negative control) at 37°C for 10min. Dihydrorhodamine (DHR 123) was then added for 10min, erythrocytes were lysed and DNA staining solution was added. The freely cell permeable nonfluorescent Dihydrorhodamine 123 becomes fluorescent when oxidized by reactive oxygen species. Stained samples were analyzed on a Navios flow cytometer (Beckman Coulter, Krefeld, Germany) within less than 30min. The respiratory burst intensity in neutrophils was determined by analysis of increase in the mean fluorescence intensity (MFI) in the FL1 Channel in the stimulated samples compared to the unstimulated control.

For analysis of neutrophil phagocytic activity, heparinized whole blood was incubated with FITC-labeled opsonized *E. coli* bacteria for 10min at 37°C or 0°C (negative control). After incubation, the reaction was stopped, erythrocytes were lysed and the DNA staining solution was added. Stained samples were analyzed on a Navios flow cytometer (Beckman Coulter, Krefeld, Germany) within less than 30min. The phagocytic activity of neutrophils was determined by the increase in MFI in the FL1 Channel in the stimulated sample compared to the unstimulated control. Data were analyzed using prism version 8. Mixed-effect-analysis and Sidak's multiple comparison test was applied to report statistical differences of *E.coli*- and PMA-induced ROS production as well as phagocytosis between mild and severe COVID-19 patients.

### *Ex vivo* functional analysis of monocytes {#sec4.4.7}

Monocytes were isolated from frozen PBMCs by negative selection using the Pan Monocyte Isolation Kit (Miltenyi, Bergisch Gladbach, Germany). The purity of isolated cells was assessed by BD Canto 2 flow cytometer, and preparations with \> 85% purity were used for experiments. Monocytes were resuspended in complete RPMI1640 medium (GIBCO) supplemented with 10% heat-inactivated fetal bovine serum (Pan Biotech), 10 U/ml penicillin and 10 μg/ml streptomycin (Sigma-Aldrich, USA), and stimulated for 8h with LPS (1 ng/ml; TLRpure; Innaxon, UK). After stimulation, cell-free supernatants were collected and tested for IL-1β, IFNγ, and TNFα, respectively, using the cytokine bead assay *Legend-Plex Mix&Match inflammation panel 1 kit* (Biolegend, USA). Cytokine-bound beads were measured with a BD Canto 2 flow cytometer and analyzed using Legend-Plex Software 8.0 (Biolegend, USA).

### Hematological analyses of the granulocyte compartment {#sec4.4.8}

Blood samples were collected into K~3~EDTA evacuated plastic tubes (Greiner Bio-One GmbH, Frickenhausen, Germany) and were subsequently analyzed using Sysmex XN-10 hematology analyzers within a XN-2000 or XN-9100 configuration (Sysmex Corporation, Kobe, Japan) as previously described ([@bib114]). Immature granulocytes (IG) were quantified by automated flow cytometry using the Sysmex WBC differential channel in XN-10 hematology analyzers within a XN-2000 or XN-9100 configuration (Sysmex Corporation, Kobe, Japan). Whole blood was treated with LysercellWDF for cell permeabilization and stained with the nucleic acid polymethine fluorescent dye FluorocellWDF according to Sysmex-proprietary protocols without modifications. Subsequent differentiation of white blood cells into lymphocytes, monocytes, neutrophils, eosinophils, and immature granulocytes was achieved by flow cytometry using a 663 nm laser. The cell populations' distinct forward-scattered light (FSC = NE-WZ, i.e., cell volume), side-scattered light (SSC = NE-WX, i.e., granularity), and side-fluorescent light (SFL = NE-WY, i.e., nucleic acid content) properties allowed determining the width of neutrophil cytometric dispersions applying Sysmex-proprietary algorithms. Data were analyzed using prism version 8. Mann Whitney test was used to report differences in IG count, whereas mixed-effect-analysis and Sidak's multiple comparison test was applied to report statistical differences of NE-WX, NE-WY and NE-WZ between mild and severe COVID-19 patients.

### 10x Genomics Chromium single-cell RNA-seq {#sec4.4.9}

PBMC were isolated and prepared as described above. Afterward, patient samples were hashtagged with TotalSeq-A antibodies (Biolegend) according to the manufacturer's protocol for TotalSeq^TM^-A antibodies and cell hashing with 10x Single Cell 3′ Reagent Kit v3.1. 50μL cell suspension with 1x10^6^ cells were resuspended in staining buffer (2% BSA, Jackson Immuno Research; 0.01% Tween-20, Sigma-Aldrich; 1x DPBS, GIBCO) and 5 μL Human TruStain FcX^TM^ FcBlocking (Biolegend) reagent were added. The blocking was performed for 10min at 4°C. In the next step 1μg unique TotalSeq-A antibody was added to each sample and incubated for 30min at 4°C. After the incubation time 1.5mL staining buffer were added and centrifuged for 5min at 350*g* and 4°C. Washing was repeated for a total of 3 washes. Subsequently, the cells were resuspended in an appropriate volume of 1x DPBS (GIBCO), passed through a 40μm mesh (Flowmi^TM^ Cell Strainer, Merck) and counted, using a Neubauer Hemocytometer (Marienfeld). Cell counts were adjusted and hashtagged cells were pooled equally. The cell suspension was super-loaded, with 50,000 cells, in the Chromium^TM^ Controller for partitioning single cells into nanoliter-scale Gel Bead-In-Emulsions (GEMs). Single Cell 3′ reagent kit v3.1 was used for reverse transcription, cDNA amplification and library construction of the gene expression libraries (10x Genomics) following the detailed protocol provided by 10x Genomics. Hashtag libraries were prepared according to the cell hashing protocol for 10x Single Cell 3′ Reagent Kit v3.1 provided by Biolegend, including primer sequences and reagent specifications. Biometra Trio Thermal Cycler was used for amplification and incubation steps (Analytik Jena). Libraries were quantified by Qubit^TM^ 2.0 Fluorometer (ThermoFisher) and quality was checked using 2100 Bioanalyzer with High Sensitivity DNA kit (Agilent). Sequencing was performed in paired-end mode with a S1 and S2 flow cell (2 × 50 cycles) using NovaSeq 6000 sequencer (Illumina).

### BD Rhapsody single-cell RNA-seq {#sec4.4.10}

Whole transcriptome analyses, using the BD Rhapsody Single-Cell Analysis System (BD, Biosciences) were performed on PBMC and whole blood samples prepared as described above. Cells from each sample were labeled with sample tags (BD Human Single-Cell Multiplexing Kit) following the manufacturer's protocol. Briefly, a total number of 1x10^6^ cells were resuspended in 180μl of Stain Buffer (FBS) (BD PharMingen). The sample tags were added to the respective samples and incubated for 20min at room temperature. After incubation, 200μl stain buffer was added to each sample and centrifuged for 5min at 300 g and 4°C. Samples were washed one more time. Subsequently cells were resuspended in 300μl of cold BD Sample Buffer and counted using Improved Neubauer Hemocytometer (INCYTO). Labeled samples were pooled equally in 650μl cold BD Sample Buffer. For each pooled sample two BD Rhapsody cartridges were super-loaded with approximately 60,000 cells each. Single cells were isolated using Single-Cell Capture and cDNA Synthesis with the BD Rhapsody Express Single-Cell Analysis System according to the manufacturer's recommendations (BD Biosciences). cDNA libraries were prepared using the BD Rhapsody Whole Transcriptome Analysis Amplification Kit following the BD Rhapsody System mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol (BD Biosciences). The final libraries were quantified using a Qubit Fluorometer with the Qubit dsDNA HS Kit (ThermoFisher) and the size-distribution was measured using the Agilent high sensitivity D5000 assay on a TapeStation 4200 system (Agilent technologies). Sequencing was performed in paired-end mode (2^∗^75 cycles) on a NovaSeq 6000 and NextSeq 500 System (Illumina) with NovaSeq 6000 S2 Reagent Kit (200 cycles) and NextSeq 500/550 High Output Kit v2.5 (150 Cycles) chemistry, respectively.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Data pre-processing of 10x Genomics Chromium scRNA-seq data {#sec4.5.1}

CellRanger v3.1.0 (10x Genomics) was used to process scRNA-seq. To generate a digital gene expression (DGE) matrix for each sample, we mapped their reads to a combined reference of GRCh38 genome and SARS-CoV-2 genome and recorded the number of UMIs for each gene in each cell.

### Data pre-processing of BD Rhapsody scRNA-seq data {#sec4.5.2}

After demultiplexing of bcl files using Bcl2fastq2 V2.20 from Illumina and quality control, paired-end scRNA-seq reads were filtered for valid cell barcodes using the barcode whitelist provided by BD. Cutadapt 1.16 was then used to trim NexteraPE-PE adaptor sequences where needed and to filter reads for a PHRED score of 20 or above ([@bib72]). Then, STAR 2.6.1b was used for alignment against the Gencode v27 reference genome ([@bib30]). Dropseq-tools 2.0.0 were used to quantify gene expression and collapse to UMI count data (<https://github.com/broadinstitute/Drop-seq/>). For hashtag-oligo based demultiplexing of single-cell transcriptomes and subsequent assignment of cell barcodes to their sample of origin the respective multiplexing tag sequences were added to the reference genome and quantified as well.

### ScRNA-seq data analysis of 10x Chromium data of cohort 1 {#sec4.5.3}

ScRNA-seq UMI count matrices were imported to R 3.6.2 and gene expression data analysis was performed using the R/Seurat package 3.1.4 ([@bib15]; [@bib37]). Demultiplexing of cells was performed using the *HTODemux* function implemented in Seurat.

### Data quality control {#sec4.5.4}

We excluded cells based on the following quality criteria: more than 25% mitochondrial reads, more than 25% *HBA/HBB* gene reads, less than 250 expressed genes or more than 5,000 expressed genes and less than 500 detected transcripts. We further excluded genes that were expressed in less than five cells. In addition, mitochondrial genes have been excluded from further analysis.

### Normalization {#sec4.5.5}

LogNormalization (Seurat function) was applied before downstream analysis. The original gene counts for each cell were normalized by total UMI counts, multiplied by 10,000 (TP10K) and then log transformed by log10(TP10k+1).

### Data integration {#sec4.5.6}

After normalization, the count data was scaled regressing for total UMI counts and principal component analysis (PCA) was performed based on the 2,000 most variable features identified using the vst method implemented in Seurat. Subsequently, the scRNA-seq data from cohort 1 was integrated with publicly available 10x scRNaseq data of healthy controls using the 'harmony' algorithm ([@bib52]) based on the first 20 principal components to correct for technical differences in the gene expression counts of the different data sources (Control samples from [@bib99]), 10x v3.1 PBMC benchmarking data from healthy controls and 10x v3.1 scRNA-seq data from cohort 1). We downloaded the count matrices for the publicly available scRNA-seq data and filtered the cells using the above-mentioned quality criteria prior to data integration. For two-dimensional data visualization we performed UMAP based on the first 20 dimensions of the 'harmony' data reduction. The cells were clustered using the Louvain algorithm based on the first 20 'harmony" dimensions with a resolution of 0.4.

### Differential expression tests and cluster marker genes {#sec4.5.7}

Differential expression (DE) tests were performed using FindMarkers/FindAllMarkers functions in Seurat with Wilcoxon Rank Sum test. Genes with \> 0.25 log-fold changes, at least 25% expressed in tested groups, and Bonferroni-corrected p values \< 0.05 were regarded as significantly differentially expressed genes (DEGs). Cluster marker genes were identified by applying the DE tests for upregulated genes between cells in one cluster to all other clusters in the dataset. Top ranked genes (by log-fold changes) from each cluster of interest were extracted for further illustration. The exact number and definition of samples used in the analysis are specified in the legend of [Figure 2](#fig2){ref-type="fig"}A and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Cluster annotation {#sec4.5.8}

Clusters were annotated based on a double-checking strategy: 1) by comparing cluster marker genes with public sources, and 2) by directly visualizing the expression pattern of CyTOF marker genes.

### GO enrichment analysis {#sec4.5.9}

Significant DEGs between each monocyte cluster and the rest of monocyte subpopulations were identified by FindMarkers function from the Seurat package using Wilcoxon Rank Sum test statistics for genes expressed in at least 25% of all monocyte clusters. P values were corrected for multiple testing using Bonferroni correction and genes with corrected p values lower or equal 0.05 have been taken as significant DEGs for GO enrichment test by R package/ClusterProfiler v.3.10.1 ([@bib133]).

### Correlation analysis of marker genes for monocyte and neutrophils between cohort 1 and 2 {#sec4.5.10}

To systematically compare the similarity of marker gene expression in the identified monocyte/neutrophils subpopulations between the two cohorts, the Spearman correlation coefficients were calculated based on the union of the top 50 marker genes of each cluster sorted by fold change in the two cohorts, based on their average expression of all cells in the specific subpopulation. The pairwise comparisons were performed, and the correlation coefficients were displayed using a heatmap.

### Subset analysis of the neutrophils within the PBMC dataset of cohort 1 {#sec4.5.11}

The neutrophil space was investigated by subsetting the PBMC dataset to those clusters identified as neutrophils and immature neutrophils (cluster 5 and 6). Within those subsets, we selected top 2,000 variable genes and repeated the clustering using the SNN-graph based Louvain algorithm mentioned above with a resolution of 0.6. The dimensionality of the data was then reduced to 10 PCs, which served as input for the UMAP calculation. To categorize the observed neutrophil clusters into the respective cell cycle states, we applied the CellCycleScoring function of Seurat and visualized the results as pie charts.

A gene signature enrichment analysis using the 'AUCell' method ([@bib2]) was applied to link observed neutrophil clusters to existing studies and neutrophils of cohort 2. We set the threshold for the calculation of the area under the curve (AUC) to marker genes from collected publications and top 30 of the ranked maker genes from each of neutrophil clusters from cohort 2. The resulting AUC values were normalized the maximum possible AUC to 1 and subsequently visualized in violin plots or UMAP plots.

### ScRNA-seq data analysis of Rhapsody data of cohort 2 {#sec4.5.12}

#### General steps for Rhapsody data downstream analysis {#sec4.5.12.1}

ScRNA-seq UMI count matrices were imported to R 3.6.2 and gene expression data analysis was performed using the R/Seurat package 3.1.2 ([@bib15]). Demultiplexing of cells was performed using the *HTODemux* function implemented in Seurat. After identification of singlets, cells with more than 25% mitochondrial reads, less than 250 expressed genes or more than 5,000 expressed genes and less than 500 detected transcripts were excluded from the analysis and only those genes present in more than 5 cells were considered for downstream analysis. The following normalization, scaling and dimensionality reduction steps were performed independently for each of the data subsets used for the different analyses as indicated respectively. In general, gene expression values were normalized by total UMI counts per cell, multiplied by 10,000 (TP10K) and then log transformed by log10(TP10k+1). Subsequently, the data was scaled, centered and regressed against the number of detected transcripts per cell to correct for heterogeneity associated with differences in sequencing depth. For dimensionality reduction, PCA was performed on the top 2,000 variable genes identified using the vst method implemented in Seurat. Subsequently, UMAP was used for two-dimensional representation of the data structure. Cell type annotation was based on the respective clustering results combined with data-driven cell type classification algorithms based on reference transcriptome data ([@bib5]) and expression of known marker genes.

### scRNA-seq analysis of the complete BD Rhapsody dataset of cohort 2 including data from frozen and fresh PBMC and whole blood {#sec4.5.13}

ScRNA-seq count data of 229,731 cells derived from fresh and frozen PBMC samples purified by density gradient centrifugation and whole blood after erythrocyte lysis of cohort 2 (Bonn, BD Rhapsody) were combined, normalized and scaled as described above (see [Figure S6](#figs6){ref-type="fig"}A). After variable gene selection and PCA, UMAP was performed based on the first 20 principal components (PCs). No batch correction or data integration strategies were applied to the data. Visualization of the cells ([Figure S6](#figs6){ref-type="fig"}A) showed overlay of cells of the same type (e.g., T cells clustered within the same cluster, irrespective of cell isolation procedure). In other words, cell type distribution was unaffected by the technical differences in sample handling. Data quality and information content was visualized as violin plots showing the number of detected genes, transcripts (UMIs) and genic reads per sample handling strategy split by PBMC and granulocyte fraction.

### scRNA-seq analysis of fresh and frozen PBMC samples {#sec4.5.14}

ScRNA-seq count data of 139,848 cells derived from fresh and frozen PBMC samples of cohort 2 (Bonn, BD Rhapsody) purified by density gradient centrifugation were normalized and scaled as described above. After variable gene selection and PCA, UMAP was performed and the cells were clustered using the Louvain algorithm based on the first 20 PCs and a resolution of 0.4. Cluster identities were determined by reference-based cell classification and inference of cluster-specific marker genes using the Wilcoxon rank sum test using the following cutoffs: genes have to be expressed in more than 20% of the cells of the respective cluster, exceed a logarithmic fold change cutoff to at least 0.2, and exhibited a difference of \> 10% in the detection between two clusters. The exact number and definition of samples used in the analysis are specified in the legend of [Figure 2](#fig2){ref-type="fig"}D and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Quantification of the percentages of cell clusters in the PBMC scRNA-seq data of both cohorts separated by disease group {#sec4.5.15}

To compare shifts in the monocyte and neutrophil populations in the PBMC compartment of COVID-19 patients, the percentages of the cellular subsets - as identified by clustering and cluster annotation explained above for the two independent scRNA-seq datasets (cohort 1 and cohort 2) - of the total number of PBMC in each dataset were quantified per sample and visualized together in boxplots. To determine the statistical significance of differences in cell proportions between the different conditions, a Dirichlet regression model was used, due to the fact that the proportions are not independent of one another. The R/R*DirichletReg* ([@bib71]) package was used. The p values were corrected for multiple testing using the Benjamini-Hochberg procedure.

### Subset analysis of the monocytes within the PBMC dataset of cohort 2 {#sec4.5.16}

The monocyte space was investigated by subsetting the PBMC dataset to those clusters identified as monocytes (cluster 0-4), removing cells with strong multi-lineage marker expressions, and repeating the variable gene selection (top 2,000 variable genes), regression for the number of UMIs and scaling as described above. The dimensionality of the data was then reduced to 8 PCs, which served as input for the UMAP calculation. The SNN-graph based Louvain clustering of the monocytes was performed using a resolution of 0.2. Marker genes per cluster were calculated using the Wilcoxon rank sum test using the following cutoffs: genes have to be expressed in \> 20% of the cells, exceed a logarithmic fold change cutoff to at least 0.25, and exhibited a difference of \> 10% in the detection between two clusters. The exact number and definition of samples used in the analysis are specified in the legend of [Figure 4](#fig4){ref-type="fig"}A and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Time kinetics analysis of identified monocyte clusters {#sec4.5.17}

For each patient and time point of sample collection, the proportional occupancy of the monocyte clusters was calculated, and the relative proportions were subsequently visualized as a function of time.

### Analysis of scRNA-seq data from fresh PBMC and whole blood samples of cohort 2 {#sec4.5.18}

ScRNA-seq count data derived from fresh PBMC samples purified by density gradient centrifugation and whole blood after erythrocyte lysis of cohort 2 (BD Rhapsody) were normalized, scaled, and regressed for the number of UMI per cell as described above. After PCA based on the top 2,000 variable genes, UMAP was performed using the first 30 PCs. Cell clusters were determined using Louvain clustering implemented in Seurat based on the first 30 principle components and a resolution of 0.8. Cluster identities were assigned as detailed above using reference-based classification and marker gene expression. Subsequently, the dataset was subsetted for whole blood samples after erythrocyte lysis and clusters identified as neutrophils and immature neutrophils, and re-scaled and regressed. After PCA on the top 2,000 variable genes, the neutrophil subset data was further processed using the data integration approach implemented in Seurat ([@bib116]) based on the first 30 PCs removing potential technical biases of separate experimental runs. UMAP and clustering were performed as described above on the top 12 PCs using a resolution of 0.3. Differentially expressed genes between clusters were defined using a Wilcoxon rank sum test for differential gene expression implemented in Seurat. Genes had to be expressed in \> 10% of the cells of a cluster, exceed a logarithmic threshold \> 0.1. The exact number and definition of samples used in the analysis are specified in the legend of [Figure 7](#fig7){ref-type="fig"}A and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Quantification of percentages of cell subsets in whole blood scRNA-seq data of cohort 2 {#sec4.5.19}

After cell type classification of the combined scRNA-seq dataset of fresh PBMC and whole blood samples of cohort 2 described above, 89,883 cells derived from whole blood samples after erythrocyte lysis were subsetted. Percentages of cell subsets in those whole blood samples of the total number of cells were quantified per sample and visualized in boxplots separated by disease stage and group.

### Confusion matrix {#sec4.5.20}

For each cluster of neutrophils, the relative proportion across disease severity and time point was visualized as a fraction of samples from the respective condition contributing to the cluster.

### GO enrichment {#sec4.5.21}

Gene set enrichment was performed on gene sets from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database ([@bib49]), Hallmark gene sets ([@bib64]) and Gene Ontology (GO) ([@bib6]; [@bib16]) using the R package/ClusterProfiler v.3.10.1 ([@bib133]).

### Cell cycle state analysis of scRNA-seq data {#sec4.5.22}

To categorize the cells within the neutrophil clusters into the respective cell cycle states, we applied the *CellCycleScoring* function of Seurat and visualized the results as pie charts.

### Trajectory analysis {#sec4.5.23}

Trajectory analysis was performed using the *destiny* algorithm v3.0.1 ([@bib4]). In brief, the neutrophil space was subsetted to only severe patients (early and late) and only the most prominent clusters of the latter (clusters 1,2,6,8). The normalized data were scaled and regressed for UMIs and a diffusion map was calculated based on the top 2,000 variable genes with a sum of at least 10 counts over all cells. Based on the diffusion map, a diffusion pseudo time was calculated to infer a transition probability between the different cell states of the neutrophils. Subsequently, the density of the clusters along the pseudotime and marker gene expression for each cluster were visualized.

Enrichment of gene sets was performed using the 'AUCell' method ([@bib2]) implemented in the package (version 1.4.1) in R. We set the threshold for the calculation of the AUC to the top 3% of the ranked genes and normalized the maximum possible AUC to 1. The resulting AUC values were subsequently visualized in violin plots or UMAP plots.

### Transcription factor prediction analysis {#sec4.5.24}

The Cytoscape (version v3.7.1, [https://doi.org/10.1101/gr.1239303](10.1101/gr.1239303){#intref0420}) plug-in iRegulon ([@bib46]) (version 1.3) was used to predict the transcription factors potentially regulating cluster-specifically expressed gene sets in the neutrophil and monocyte subset analysis in cohort 2. The genomic regions for TF-motif search were limited to 10kb around the respective transcriptional start sites and filtered for predicted TFs with a normalized enrichment score \> 4.0. Next, we filtered for TFs, which exceeded a cumulative normalized expression cutoff of 50 in the respective cluster. Subsequently, we selected transcription factors of known relevance in the context of neutrophil and monocyte biology and constructed a network linking target genes among the cluster-specifically expressed marker genes and their predicted and expressed regulators for visualization in Cytoscape.

### Mass cytometry data analysis {#sec4.5.25}

Cytobank.org was used for de-barcoding of individual samples and manually gating of cell events to remove doublets, normalization beads and dead cells ([@bib53]). Per channel intensity ranges were aligned between batches of measurements using a reference sample acquired across all batches and the BatchAdjust function to compute scaling factors at the 95th event percentiles ([@bib111]). For semi-automated gating of populations of interest, high-resolution SPADE clustering was conducted on all indicated asinh-transformed markers ([Table S2](#mmc2){ref-type="supplementary-material"}) with 400 target nodes ([@bib96]). Individual SPADE nodes were then aggregated and annotated to cell subsets (bubbles) according to the expression of lineage-specific differentiation markers. Clustering results and FCS files were subsequently loaded into the R CytoML/flowCore environment (10.18129/B9.bioc.CytoML, 10.18129/B9.bioc.flowCore) for further downstream analyses. To generate UMAP representations all events of a given population of interest were down-sampled to 70,000 cells and then embedded using the tumap function (R uwot package, <https://cran.r-project.org/web/packages/uwot/index.html>) parameterized by local neighborhood 50, learning rate 0.5, and using the indicated markers ([Table S2](#mmc2){ref-type="supplementary-material"}) as input dimensions. For statistical analysis of cell population abundances, we fitted a generalized linear mixed-effects model (GLMM) for each population using the lme4 package ([@bib89]). P values resulting from differential abundance testing (via R multcomp and lsmeans packages) were adjusted using the Benjamini-Hochberg procedure and an FDR-cutoff of 5% across all clusters/subsets and between-group comparisons ([@bib42]; [@bib60]). Additionally, indicated surface marker positive populations were exported from Cytobank and analyzed using prism 8. Kruskal-Wallis and Dunn's multiple comparison test was used to compare differences in proportions between patient groups, whereas mixed-effect-analysis and Sidak's multiple comparison test was applied to report time-dependent differences. The exact numbers and definitions of samples used in the analyses are specified in the respective figure legends and summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Data Analysis of Flow Cytometry Data {#sec4.5.26}

Flow cytometry data analysis was performed with FlowJo V10.6.1. Cell type was defined as granulocytes (CD45^+^, CD66b^+^), non-classical monocytes (CD45^+^, CD66b^-^, CD19^-^, CD3^-^, CD56^-^, CD14^lo^, CD16^+^). Relative cell percentage or mean fluorescence intensity (MFI) was used for visualization and statistical analysis was done using unpaired t test.

### Data visualization {#sec4.5.27}

In general, the R packages Seurat and the ggplot2 package (version 3.1.0) ([@bib137]) were used to generate figures. For visualization of mass cytometry data, cluster minimum-spanning trees were rendered using Cytobank, the ComplexHeatmap package ([@bib35]) was used to display subset phenotypes and GraphPad Prism to generate boxplots of quantitative data.

Additional Resources {#sec4.6}
--------------------

Part of the patients included in this study have been recruited within the clinical trial DRKS00021688, registered at the German registry for clinical studies ([@bib55]).

In addition to the deposition of the raw sequencing data on EGA, we provide an interactive platform for data inspection and analysis via FASTGenomics. The FASTGenomics platform ([fastgenomics.org](http://fastgenomics.org){#intref0430}) provides processed count tables of the datasets generated in this study as well as key analytical results, such as UMAP coordinates and cluster identities, and the code written to analyze the respective data.

Consortia {#sec5}
=========
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